<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10985213</article-id><article-id pub-id-type="pmcid-ver">PMC10985213.1</article-id><article-id pub-id-type="pmcaid">10985213</article-id><article-id pub-id-type="pmcaiid">10985213</article-id><article-id pub-id-type="pmid">38567021</article-id><article-id pub-id-type="doi">10.3389/fcimb.2024.1282183</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>van Schaik</surname><given-names initials="EJ">E. J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/206665"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fratzke</surname><given-names initials="AP">A. P.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1197507"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gregory</surname><given-names initials="AE">A. E.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/52468"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dumaine</surname><given-names initials="JE">Jennifer E.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Samuel</surname><given-names initials="JE">J. E.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1609791"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Microbial Pathogenesis and Immunology, School of Medicine, Texas A&amp;M University, Medical Research and Education Building</institution>, <addr-line>Bryan, TX</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Charles River Laboratories</institution>, <addr-line>Reno, NV</addr-line>, <country>United States</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Physiology and Biophysics, University of California, Irvine</institution>, <addr-line>Irvine, CA</addr-line>, <country>United States</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Veterinary Pathobiology, School of Veterinary Medicine, Texas A&amp;M University (TAMU)</institution>, <addr-line>College Station, TX</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Rey Carabeo, University of Nebraska Medical Center, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Carrie Mae Long, National Institute of Allergy and Infectious Diseases (NIH), United States</p><p>Damien F. Meyer, Institut National de la Recherche Agronomique (INRA), France</p><p>J Stephen Dumler, Uniformed Services University of the Health Sciences, United States</p></fn><corresp id="fn001">*Correspondence: J. E. Samuel, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jsamuel@tamu.edu">jsamuel@tamu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">454443</issue-id><elocation-id>1282183</elocation-id><history><date date-type="received"><day>23</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>02</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-03 17:25:13.190"><day>03</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 van Schaik, Fratzke, Gregory, Dumaine and Samuel</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>van Schaik, Fratzke, Gregory, Dumaine and Samuel</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-14-1282183.pdf"/><abstract><p>Obligate intracellular bacteria have remained those for which effective vaccines are unavailable, mostly because protection does not solely rely on an antibody response. Effective antibody-based vaccines, however, have been developed against extracellular bacteria pathogens or toxins. Additionally, obligate intracellular bacteria have evolved many mechanisms to subvert the immune response, making vaccine development complex. Much of what we know about protective immunity for these pathogens has been determined using infection-resolved cases and animal models that mimic disease. These studies have laid the groundwork for antigen discovery, which, combined with recent advances in vaccinology, should allow for the development of safe and efficacious vaccines. Successful vaccines against obligate intracellular bacteria should elicit potent T cell memory responses, in addition to humoral responses. Furthermore, they ought to be designed to specifically induce strong cytotoxic CD8+ T cell responses for protective immunity. This review will describe what we know about the potentially protective immune responses to this group of bacteria. Additionally, we will argue that the novel delivery platforms used during the Sars-CoV-2 pandemic should be excellent candidates to produce protective immunity once antigens are discovered. We will then look more specifically into the vaccine development for <italic toggle="yes">Rickettsiaceae</italic>, <italic toggle="yes">Coxiella burnetti</italic>, and <italic toggle="yes">Anaplasmataceae</italic> from infancy until today. We have not included <italic toggle="yes">Chlamydia trachomatis</italic> in this review because of the many vaccine related reviews that have been written in recent years.</p></abstract><kwd-group><kwd>vaccines</kwd><kwd>obligate intracellular bacteria</kwd><kwd>vector-borne disease</kwd><kwd><italic toggle="yes">Coxiella</italic></kwd><kwd><italic toggle="yes">Anaplasmataceae</italic></kwd><kwd><italic toggle="yes">Rickettsiaceae</italic></kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Defense Threat Reduction Agency
</institution><institution-id institution-id-type="doi">10.13039/100000774</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>National Institutes of Health
</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by National Institutes of Health grant R01AI090142 (JS) and Training Grant T32 fellowship 5 OD 11083-11 (AF). This work was further supported by the Defense Threat Reduction Agency HDTRA1-14-C-0113.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="220"/><page-count count="22"/><word-count count="15069"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Clinical Microbiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The disease burden caused by many obligate intracellular bacteria described in this review has increase at least 10-fold since the year 2000 in the USA, as reported by the CDC. Ticks transmit most of these obligate intracellular bacteria, which are responsible for &gt;95% of all vector-borne disease in the USA (<xref rid="B57" ref-type="bibr">Eisen et&#160;al., 2017</xref>). The expansion of ticks&#8217; territories over the last century has contributed to this rise in cases, which will continue because of climate change resulting in the further expansion of ticks into new regions (<xref rid="B179" ref-type="bibr">Sonenshine, 2018</xref>). Another obligate intracellular bacterium not known but potentially transmitted by ticks is <italic toggle="yes">Coxiella burnetii</italic> where cases of Q fever have doubled in the USA in the same period (<xref rid="B36" ref-type="bibr">Cherry et&#160;al., 2022</xref>). On the opposite side of the world <italic toggle="yes">Orientia tsutsugamuschi</italic> causes &gt;1 million cases a year of scrub thyphus transmitted by chiggers, which is found primarily in southeast Asia but has an expanding territory and where the emergence of antibiotic-resistant strains is a significant concern (<xref rid="B115" ref-type="bibr">Luce-Fedrow et&#160;al., 2018</xref>). Recently, <italic toggle="yes">O. tsutsugamuschi</italic> was found in chiggers in North Carolina, indicating their presence in the USA, although the spread of disease has not occurred to date (<xref rid="B34" ref-type="bibr">Chen et&#160;al., 2023</xref>). The rise of infections and expansion of vector territories for these obligate intracellular bacteria are making them a rising public health concern. Additionally, at the early stages of disease, most of these infections present as non-specific flu-like illnesses, making diagnosis problematic. Therefore, although these infections can currently be treated effectively with doxycycline, the potential for under or misdiagnosis and the possibility for further acquired antibiotic resistance in these bacteria still makes vaccination the best strategy to mitigate disease (<xref rid="B183" ref-type="bibr">Strickman et&#160;al., 1995</xref>; <xref rid="B161" ref-type="bibr">Rolain et&#160;al., 2005</xref>; <xref rid="B127" ref-type="bibr">Mcclure et&#160;al., 2017</xref>). It is our view that any vaccination strategy that stimulates a Th1 mediated response with the production of pathogen specific antibodies, CD4+ T cell, and CD8+ cytotoxic T cell will be most effective for any of the obligate intracellular bacteria discussed in this review. Several strategies including novel antigen/adjuvant mixtures or delivery platforms could accomplish this goal.</p><p>Vaccination is one of the most important medical advances and has nearly eradicated several diseases responsible for significant morbidity and mortality in both humans and many animal species. A recent study estimated the number of potential human deaths eliminated by vaccination as 50 million in just the new millennium (2000-2019) (<xref rid="B190" ref-type="bibr">Toor et&#160;al., 2021</xref>). However, none of the approved vaccines for human or animal use are for the obligate intracellular bacteria discussed in this review. All these zoonotic diseases would benefit from a one health initiative. And although there is a critical need for animal vaccines for obligate bacteria in these genera discussed in this review, the focus will be on human vaccines. One of the main reasons there are no approved vaccines for this group of bacteria is their intracellular lifestyle because although antibodies can provide some protection, once intracellular a cell-mediated response will be necessary for clearance. Furthermore, since most of these bacteria actively subvert the immune system a vaccine strategy that produces a robust humoral and cell-mediated immune response will have a better chance of providing protection. Challenges at the clinical trial stage will include defining novel cell-mediated correlates of protection a challenge for any vaccine that relies on humoral and cell-mediated immunity. Additionally, humoral correlates of protection will be more difficult to establish as neutralization is often not mechanisms of protection. This review aims to provide a comprehensive description about what is known about the immune responses to natural infection and how the information can guide human vaccine development. Additionally, vaccine immunology necessary for understanding the components of protection will be discussed, followed by several new vaccinology approaches that could aid the development of successful vaccines for these pathogens.</p></sec><sec id="s2"><title>Vaccination immunology specific for obligate intracellular bacteria</title><p>Most vaccines are injected with needles, where antigens are taken up by antigen presenting cells (APCs) at the site of vaccination which can also be activated by adjuvant-type pathogen-associated molecular patterns (PAMPs) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). These activated APCs migrate to regional lymph nodes to present antigens to na&#239;ve T cells in the context of MHCI and MHCII to T cell receptors (TCR), which are assumed to be essential for cellular immunity to obligate intracellular bacteria (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). CD4+ T cells are more important for clearance of vacuolar bacteria (<italic toggle="yes">C. burnetti</italic>, and <italic toggle="yes">Anaplasmataceae</italic>), whereas CD8+ T cells are important for the clearance of cytoplasmic <italic toggle="yes">Rickettsiaceae</italic>. However, it is the view of the authors that any vaccine formulation that can stimulate both pathogen specific CD4+ and CD8+ T cells should provide more protection and either alone. The importance of various immune responses will be discussed in the pathogen specific sections. CD4+ and CD8+ T cells then mature into effector and memory populations. The memory population of T cells can be separated into 3 different types: central memory (T<sub>CM</sub>), effector memory (T<sub>EM</sub>), and tissue resident (T<sub>RM</sub>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). Effective vaccines for obligate intracellular bacteria likely require a strong T<sub>RM</sub> response, particularly since T<sub>RMS</sub> are found in the skin, lungs, liver, and intestines. T<sub>RMS</sub> rapidly respond to local antigen causing cytokine release and recruitment of circulating memory T cells (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). A strong T<sub>RM</sub> response after mucosal immunization with inactivated <italic toggle="yes">C. trachomatis</italic> has been observed, which demonstrated that in mice optimal clearance is dependent on T<sub>RMS</sub> and circulating memory T cells supporting our view that T<sub>RMS</sub> will be important for vaccine induced protection against the other obligate intracellular bacteria discussed in this review (<xref rid="B181" ref-type="bibr">Stary et&#160;al., 2015</xref>). CD4+ T helper cells also drive B cell development by providing help after B cell receptors recognize soluble antigen found in the lymph nodes. This is provided by a subset of CD4+ T helper cells called T follicular helper cells (Tfh) which allow B cells then undergo class switching and develop into antibody secreting plasma cells, long-lived plasma cells (LLPCs), and memory cells (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>) (<xref rid="B141" ref-type="bibr">Olatunde et&#160;al., 2021</xref>). LLPCs reside in bone marrow and can secrete antibodies for years, decades, or longer in humans. On the other hand, short-lived plasma cells are usually found in extrafollicular locations (<xref rid="B21" ref-type="bibr">Bortnick and Allman, 2013</xref>). It is now recognized that LLPCs provide long-term and sustained production of antibodies, and therefore any effective vaccine to an obligate intracellular that requires an antibody response should stimulate the production of LLPCs (<xref rid="B112" ref-type="bibr">Lightman et&#160;al., 2019</xref>). Passive transfer of sera to na&#239;ve mice provides protection against many obligate intracellular bacteria including <italic toggle="yes">Ehrlichia chaffenesis</italic> and <italic toggle="yes">Rickettsia conorii</italic> (<xref rid="B63" ref-type="bibr">Feng et&#160;al., 2004</xref>; <xref rid="B213" ref-type="bibr">Yager et&#160;al., 2005</xref>). However, passive transfer of sera to athymic mice was not protective for several obligate intracellular bacteria including <italic toggle="yes">Coxiellla burnetii</italic> and <italic toggle="yes">R. akari</italic> suggesting that T cells are involved in antibody mediated protection in some cases (<xref rid="B98" ref-type="bibr">Kenyon and Pedersen, 1980</xref>; <xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>) Therefore, although antibodies are important components of the protective immune response to obligate intracellular bacteria, a cell-mediated response should also be stimulated to confer the most efficacious level of protection ensuring that both branches of the immune system are involved in the protective response.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Basic vaccine immunology. Vaccination usually occurs via injection intramuscularly in humans where antigens are taken up by APCs at the site and are also activated by adjuvant PAMPs included in the vaccine which stimulate the innate immune system. These activated APCs then migrate to the regional lymph nodes to present these antigens to na&#239;ve T cells in the context of MHCI and MHCII to T cell receptors (TCR). CD4+ T cells and CD8+ T cells then develop into effector and memory populations. The memory population of T cells is separated into 3 different types: central memory (T<sub>CM</sub>, effector memory (T<sub>EM</sub>), and tissue resident (T<sub>RM</sub>). The CD4+ T helper cells also drive B cell development in germinal centers by providing help after B cell receptors recognize soluble antigen found in the lymph nodes. B cells then undergo class switching and develop into antibody secreting plasma cells and memory cells. This results in long-term immunity to the vaccine material. These memory cells can then be maintained at several sites including the bone marrow for long lived plasma cells (LLPCs) which can secrete antibodies long term. In addition, infection after vaccination results in release of cytokines at the site of infection by T<sub>RM</sub> and other cells of the innate immune system which can then recruit other memory T cells to the site of infection. The example of an infection after vaccination shows <italic toggle="yes">C. burnetii</italic> in the lungs, particularly in the alveoli where alveolar macrophages uptake <italic toggle="yes">C. burnetii</italic> and key players in the Th1 type response produced after vaccination which provides protection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-14-1282183-g001.jpg"/></fig><p>A cell-mediated immune response with CD4+ and/or CD8+ T cells providing most of the protection is generally required to control disease caused by obligate intracellular bacteria. Therefore, an effective immune response that requires CD4+ T cells should skew towards a Th1 phenotype with CD4+ T cells that secrete IFN&#947; for clearance of obligate intracellular bacteria, in addition, Th1 responses stimulate cytotoxic CD8+ T cells through the secretion of IFN&#947;, and IL-12 (<xref rid="B192" ref-type="bibr">Turner et&#160;al., 2021</xref>). A Th1 skew is also partially dependent on Th17 cells, which are beneficial to protective immune responses to obligate intracellular bacteria including <italic toggle="yes">C. trachomatis</italic> by contributing to Th1 modulation, neutrophil recruitment, and dendritic cell (DC) regulation (<xref rid="B111" ref-type="bibr">Li et&#160;al., 2018</xref>; <xref rid="B136" ref-type="bibr">Nguyen et&#160;al., 2021</xref>). DCs are the APCs that drive this type of response and determine what type of CD4+ T helper cells develop. CD4+ T helper cells come in a range of unique forms including Th1, Th2, Th17, Treg, and Tfh to name a few (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). The cytokines present during T cell expansion, after binding of the TCR to peptide bound in MHCII, determine the types of T helper cells that result. Conventional DCs (cDCs) are the most abundant DCs and are found in all tissues, therefore, these are the APCs that ingest antigen at the site of vaccination. Induction of Th1 cells occurs after cDC uptake of antigen with stimulation of TLR3, TLR9, or TLR11/12 and self-stimulation with IFN&#947; (<xref rid="B86" ref-type="bibr">Hilligan and Ronchese, 2020</xref>). Adjuvants that stimulate those TLRs are logical adjuvants to include in vaccines against obligate intracellular bacteria. This type of stimulation causes the cDC to release IL-12 and IL-27, both necessary to skew CD4+ T helper cells into Th1. In addition, vaccination that induces the development of CD4+ cytotoxic T lymphocytes (CTLs), which are induced after chronic viral infections with HIV-1 and described as CD4+CD28-Perforin+ T cells, should be beneficial against intracellular bacterial infections (<xref rid="B7" ref-type="bibr">Appay et&#160;al., 2002</xref>). These CTL CD4+ T cells are induced after a Th1 response. Th1 cells are also important for enhancing CD8+ T cell-mediated immunity by secreting IFN&#947;, TNF&#945;, IL-2, IL-3, and GM-CSF (<xref rid="B216" ref-type="bibr">Zander et&#160;al., 2019</xref>). In addition to shaping the CD4+ T helper cell response, cDCs are also the most effective at cross-presentation of antigens on MHCI through the vacuolar and endosome-to-cytosol pathways and are also required for CD8+ cytotoxic T cell response (<xref rid="B60" ref-type="bibr">Embgenbroich and Burgdorf, 2018</xref>). Therefore, any delivery system that targets antigens to cDCs could be valuable in a vaccine to any obligate intracellular bacterium discussed in this review since targeting a Th1/Th17 with a strong cytotoxic T cell response should be required for protection.</p><p>Vaccine formulations will likely have to include both T cell and B cell antigens to confer protection against obligate intracellular bacteria highlighting that both cell-mediated and humoral responses are optimal to clear obligate intracellular bacteria. The concept that a humoral plus CD4+ T and CD8+ T cells response confers optimal protection is exemplified by a vaccine developed against <italic toggle="yes">Mycobacterium tuberculosis</italic>. Engineering the BCG vaccine strain to produce listeriolysin O and deleting Urease C created VMP1002. This live attenuated vaccine strain was still able to confer a humoral and Th1 CD4+ T cell response like BCG, but additionally stimulates CD8+ cytotoxic T cells and afforded better protection than BCG in animal models (<xref rid="B79" ref-type="bibr">Grode et&#160;al., 2005</xref>). This vaccine is now in phII/phIII clinical trials in India. We believe any vaccine strategies that stimulate a strong humoral plus CD4+ Th1 response and additionally stimulate a CD8+ cytotoxic response will be the most efficacious (<xref rid="B137" ref-type="bibr">Nieuwenhuizen et&#160;al., 2017</xref>). Therefore, any vaccine developed should induce humoral and cell-mediated responses to provide the best protection.</p></sec><sec id="s3"><title>Correlates of protection that should be developed for obligate intracellular bacterial vaccines</title><p>Defining the CoPs is an important step in licensing an efficacious vaccine. Understanding which branch(es) of the immune system are essential in a protective response determines what are the CoPs. If CoPs are well defined, it is simpler to develop efficacious vaccines then if empirical studies are required for each new antigen. For example, serum antibody concentrations of 0.15 to 1.0 mg/mL to the polysaccharide of <italic toggle="yes">H. influenzae</italic> type b (HiB) are a CoP that can be used to develop new vaccines against HiB polysaccharide (<xref rid="B77" ref-type="bibr">Granoff and Lucas, 1995</xref>). More specifically this is a &#8220;mechanistic CoP&#8221; (mCoP), meaning it is a specific immune function that confers protection. Antibodies still represent the primary correlate of immunity for most vaccines that are licensed (<xref rid="B147" ref-type="bibr">Plotkin, 2013</xref>). In contrast, a non-mechanistic CoP (nCoP) may be correlated to protection or contributes to protection but is not a direct measurement of an immune response (<xref rid="B148" ref-type="bibr">Plotkin and Gilbert, 2012</xref>). Infection resolved cases can be used as a starting point to define CoPs for obligate intracellular bacteria, that is if infection resolved cases provide decent protection, which is not the situation of all the pathogens in this review. In addition, the ability to subvert the immune system creates issues because even if infection resolved cases provide protection this may not be the best protection because of inherent subversion mechanisms. CoPs for obligate intracellular bacterial vaccines will need to be defined for licensing and will rely not only on humoral responses which are well defined CoPs but also on cell-mediated responses and to date there are no approved vaccines with only cell-mediated CoPs.</p><p>An appropriate animal model that mimics human disease is essential to determining CoPs. Vaccination in an appropriate animal model can be used to evaluate CoPs through a variety of experimental techniques including depletion studies, antibody titers, and cellular assays. This is often challenging for obligate intracellular bacteria, especially those that are transmitted through vectors; however, advancements have been made and will be highlighted in pathogen specific sections. Although antibodies can have several functions, one of the most common CoPs are neutralizing antibodies. Neutralization implies coating the virus, bacteria, or toxin with antibodies and preventing them from binding to host cells. This is the CoP for of all the vaccines approved for preventing Sars-Cov-2 infection for the recent pandemic (<xref rid="B30" ref-type="bibr">Carrillo et&#160;al., 2021</xref>). Other antibody mediated mechanisms include opsonization and activation of the complement cascade. The mechanisms of antibody mediated immunity to obligate intracellular bacteria are often difficult to ascertain because many of these pathogens grow within immune cells even after binding antibodies (<xref rid="B174" ref-type="bibr">Shannon et&#160;al., 2009</xref>). Defining appropriate humoral mediated correlates of protection will be essential for licensing of any obligate bacterial vaccine that depends on this type of immunity. Cell-mediated CoPs are not as well defined, which has made the development of viral and obligate intracellular bacterial vaccines that will rely on cell-mediated protection difficult to evaluate (<xref rid="B12" ref-type="bibr">Barker et&#160;al., 2009</xref>).</p><p>To date there is no licensed vaccine that produces only T cell protection on the market. However, induction of CD4+ T cells has been used as a CoP for Shingrix the vaccine licensed for use against shingles in adults over 50 (<xref rid="B139" ref-type="bibr">Ogunjimi and Beutels, 2018</xref>). The gold standard for testing antigen specific T cell responses after vaccination is an ELIspot usually for IFN&#947; which can be used in mice, non-human primates (NHPs), and humans during vaccine development (<xref rid="B64" ref-type="bibr">Flaxman and Ewer, 2018</xref>). The major disadvantage of ELIspots is that there is no information about the phenotypes of the cells secreting IFN&#947;. This can be circumvented by using flow cytometry to separate cells into CD4+ and CD8+ populations that express IL-2, IFN&#947;, IL-4, IL-17, perforin, and granzyme B (<xref rid="B64" ref-type="bibr">Flaxman and Ewer, 2018</xref>). Flow cytometry can also be used to define memory populations (<xref rid="B64" ref-type="bibr">Flaxman and Ewer, 2018</xref>). Given that 40 different markers can now be measured using mass cytometry (CyTOF), the use of flow cytometry to identify CoPs during vaccine development will only increase and is the obvious choice for development of cellular CoPs for obligate intracellular bacteria. The above CoPs for humoral and cell-mediated responses should be used to develop safe and efficacious vaccines for all the obligate intracellular pathogens.</p></sec><sec id="s4"><title>Antigen selection</title><p>How do you pick antigens to be included in a vaccine? One of the earliest vaccine approaches to this problem was in fact to not pick at all and to inactivate the entire bacterium creating a whole-cell vaccine (WCV). A bacterial pathogen is cultivated in large quantities and then inactivated by one of several methods including but not limited to formalin or another chemical inactivation, heat, or irradiation (<xref rid="B101" ref-type="bibr">Khan et&#160;al., 2022</xref>). The advantage of these types of vaccines is that they are highly immunogenic and usually do not require adjuvants or boosts. Surprisingly, this is effective for several obligate intracellular bacteria including <italic toggle="yes">C. burnetii</italic> (Q-VAX<sup>&#174;</sup>), however, Q-VAX<sup>&#174;</sup> produces significant reactogenic responses in previously sensitized individuals and, therefore, was never licensed for use in the USA (<xref rid="B69" ref-type="bibr">Fratzke et&#160;al., 2022</xref>). The reactogenicity of WCVs can be reduced or eliminated and appropriate effector memory stimulated using specific antigens and epitopes alone or in solubilized cellular antigen extracts, as was demonstrated recently demonstrated in preclinical animal models for <italic toggle="yes">C. burnetii</italic> (<xref rid="B78" ref-type="bibr">Gregory et&#160;al., 2021</xref>). Identification of antigens can be accomplished by many approaches. Early strategies to identify dominant and subdominant antigens described as the immunome have been employed for many obligate intracellular bacteria using antiserum from previously infected individuals to identify protein antigens (<xref rid="B14" ref-type="bibr">Beare et&#160;al., 2008</xref>; <xref rid="B117" ref-type="bibr">Luo et&#160;al., 2021</xref>). However, there are inherent limitations in these approaches for the obligate intracellular bacteria, where immunogenic proteins are not necessarily protective and where antibody responses alone usually do not afford complete protection (<xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>). Surface exposed proteins, or sugar moieties including lipopolysaccharide (LPS) are good antigenic targets for humoral responses to the obligate intracellular bacteria that produce LPS, which excludes <italic toggle="yes">Anaplasma</italic> spp., <italic toggle="yes">Ehrlichia</italic> spp. and <italic toggle="yes">O. tsutsugamuschi</italic>, however, surface exposed protein antigens are still likely candidates for these bacteria (<xref rid="B116" ref-type="bibr">Luo et&#160;al., 2020</xref>). For example, the LPS from <italic toggle="yes">C. burnetii</italic> has been demonstrated to confer protection in both mice and guinea pigs (<xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>; <xref rid="B91" ref-type="bibr">Jan et&#160;al., 2023</xref>).</p><p>The advance of high-throughput sequencing gave way to the era of reverse vaccinology (<xref rid="B154" ref-type="bibr">Rappuoli, 2000</xref>). Reverse vaccinology has been used to identify such antigens as those used in the MenB vaccine against <italic toggle="yes">Neisseria meningitidis</italic> which represents a milestone in new vaccinology approaches (<xref rid="B123" ref-type="bibr">Masignani et&#160;al., 2019</xref>). Reverse vaccinology has been used extensively to identify antigens from obligate intracellular bacteria and has identified components of secretion systems and their secreted effector proteins as novel antigens (<xref rid="B100" ref-type="bibr">Khan et&#160;al., 2023</xref>; <xref rid="B166" ref-type="bibr">Sabzi et&#160;al., 2023</xref>). We are now in the era of rational vaccine design, which builds on reverse vaccinology with the addition of machine learning algorithms to identify antibody and T cell epitopes. The SARS-CoV-2 pandemic significantly advanced these approaches by providing rich data to employ novel machine-learning techniques to predict B and T cell epitopes using a single framework like DeepVacPred to the forefront (<xref rid="B214" ref-type="bibr">Yang et&#160;al., 2021</xref>). We, and others, predict this could accelerate the development and testing of novel vaccines for obligate intracellular bacteria. Mapping of epitopes for B and T cells, commonly referred to as immunoinformatics, is the basis for the design of epitope-based vaccines (<xref rid="B145" ref-type="bibr">Parvizpour et&#160;al., 2020</xref>). This approach does not require an entire antigenic protein and can remove immunodominant areas of antigens that do not confer protection.</p><p>More specifically, immunopeptidomics, which refers to the investigation and dynamics of all peptides presented by major histocompatibility complex (MHC) class I and class II using mass spectrometry will also add strategies for vaccines against obligate intracellular pathogens (<xref rid="B106" ref-type="bibr">Kovalchik et&#160;al., 2020</xref>). This technique has been applied recently in the development of a tuberculosis vaccine wherein 43 MHCI and 94 MCHII epitopes were identified in <italic toggle="yes">M. tuberculosis</italic> infected cells (<xref rid="B126" ref-type="bibr">Mayer and Impens, 2021</xref>). As presented in each of the following pathogen-specific sections, these advances have revolutionized the development of vaccines for obligate intracellular bacteria resulting in several safe and efficacious vaccine formulations ready for human-phased trials. Notwithstanding, pathogen adaption that results in reduced immunogenicity may remain an issue that requires combining the existing tools or developing new technology to overcome.</p></sec><sec id="s5"><title>Adjuvants</title><p>Adjuvants are vaccine components that stimulate the innate immune system to enhance the magnitude, extent, and longevity of the adaptive response to the antigens. As mentioned above, these are required additives for the new era of antigen and epitope-based vaccines. Adjuvants come in 3 basic formats: 1. as a depot that recruits antigen-presenting cells (APCs), 2. as a delivery system that helps antigen uptake by APCs, or 3. stimulate innate immune responses through pattern recognition receptors (PRRs). Once the PRRs of the innate immune system are stimulated in cDCs an adaptive immune response can result in the maturation of number of CD4+ and CD8+ T cell subsets in addition to B cells (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><p>Alum, an insoluble aluminum salt, was the first adjuvant licensed for use in the 1920s and, until very recently, the only adjuvant licensed for use in humans. Surprisingly, the exact mechanism of Alum remains poorly understood despite decades of licensure and use. Unlike most of the new adjuvants that activate one or more PRR, it has long been assumed that Alum causes a depot effect. However, it is clear that the mechanism of action of Alum is more complex and involves enhancing the delivery of APCs, production of IL-1&#946;, and induction of cell death releasing DNA and other damage-associated molecular patterns (DAMPs), that act as endogenous adjuvants (<xref rid="B48" ref-type="bibr">Del Giudice et&#160;al., 2018</xref>). There are currently 5 other adjuvants licensed for use in humans including MF59 which is included in the seasonal flu vaccine for older adults Fluad (licensed in Europe), AS01 in the shingles vaccine Singrix, AS03 in the pandemic influenza vaccine Pandemrix, AS04 in the HPV vaccine, and finally CpG in the HBV vaccine (<xref rid="B150" ref-type="bibr">Pulendran et&#160;al., 2021</xref>). In addition to these adjuvants, many other adjuvants are in the pre-clinical stages of development to ensure their safety and tolerance.</p><p>Overall, the goal of an adjuvant inclusion in a vaccine for most obligate intracellular bacteria is to elicit a strong Th1 cellular response resulting in antigen specific antibodies, CD4+ and/or CD8+ T cells. A strong cytotoxic CD8+ T cell response to antigens may be ideal but requires cross-presentation for subunit vaccines. This response requires the presentation of peptides in MHCI restricted fashion on APCs, usually cDCs, with proper cytokines and co-stimulation to induce T cell differentiation (<xref rid="B217" ref-type="bibr">Zhang and Bevan, 2011</xref>). Classically this requires peptides loaded from the cytosol into the ER and then MHCI. However, this process can occur directly from peptides in a phagosome or by transfer of peptides into the cytosol. Both processes are considered cross-presentation, which is inefficient with subunit vaccines and does not result in long-term memory CD8+ T cells. Numerous adjuvants are now under development as carriers that enhance the cross-presentation of antigens a formulation that will likely be necessary to develop safe and efficacious subunit and/or epitope vaccines for the obligate intracellular pathogens discussed in this review (<xref rid="B60" ref-type="bibr">Embgenbroich and Burgdorf, 2018</xref>).</p></sec><sec id="s6"><title>Delivery platforms</title><p>Vaccine delivery platforms comprise two different branches. One branch tests novel delivery platforms including edible vaccines, microneedle patches, or intradermal vaccines. The alternative is the basic formulation of the vaccine material and the focus of this section. For example, the SARS-CoV-2 pandemic saw the licensing of the first 2 mRNA vaccines for human use in the USA produced by Moderna, Inc. and BioNTech SE/Pfizer Inc (<xref rid="B11" ref-type="bibr">Barbier et&#160;al., 2022</xref>). The basic principle of an mRNA vaccine is the delivery of mRNA into the cell by a lipid nanoparticle resulting in the production of a protein in the cytoplasm that can be presented by MHCI to stimulate a cytotoxic CD8+ T cell response, in addition to stimulating CD4+ T cells and humoral responses (<xref rid="B197" ref-type="bibr">Verbeke et&#160;al., 2022</xref>). Furthermore, the lipid nanoparticle and the foreign mRNA can stimulate several innate immune-signaling cascades acting as adjuvants (<xref rid="B110" ref-type="bibr">Li et&#160;al., 2022</xref>). The ability to stimulate a variety of innate immune pathways followed by stimulation of antigen specific humoral, CD4+ and CD8+ T cell responses in addition to the ease of production should make mRNA vaccines ideal for vaccines developed against obligate intracellular bacteria once novel techniques to discovery antigens are used (<xref rid="B107" ref-type="bibr">Kowalzik et&#160;al., 2021</xref>). A DNA vaccine delivery method was also licensed during the SARS-Cov-2 pandemic using a non-replicating chimpanzee-Ad (adenoviral vector) in the licensed Oxford-AstraZeneca vaccine (<xref rid="B194" ref-type="bibr">Van Doremalen et&#160;al., 2020</xref>). DNA vaccines work with the same basic principle as mRNA vaccines, however, the DNA must first be transcribed in the nucleus and then translated into protein in the cytoplasm. This again allows the loading of MHCI to stimulate a cytotoxic CD8+ T cell response in addition to an antibody response. The only caveat with adenoviral vector vaccines is the potential for previous exposure and pre-existing immunity to the non-replicating viral vector which may limit the utility of these platforms as was seen with HIV-ad5 vaccines where having anti-ad5 antibodies actually increased the acquisition of HIV (<xref rid="B22" ref-type="bibr">Buchbinder et&#160;al., 2008</xref>; <xref rid="B128" ref-type="bibr">Mcelrath et&#160;al., 2008</xref>).</p><p>A novel delivery platform uses outer membrane vesicles (OMVs) which are produced by all Gram-negative bacteria. This technology not only has value for creating innovative vaccines against bacteria pathogens but is also being developed as a delivery platform for cancer vaccines (<xref rid="B220" ref-type="bibr">Zhu et&#160;al., 2021</xref>). OMVs work as a delivery platform because they can package antigens and also act directly as an adjuvant as they are composed of LPS a TLR4 agonist in addition to several other PAMPs that can stimulate TLR2 or TLR5 on the cell surface and caspase-11 and NODs in the cytoplasm (<xref rid="B193" ref-type="bibr">Vanaja et&#160;al., 2016</xref>). Antigens can be expressed on surrogate bacteria to produce OMVs, which is a strategy that could be applied to obligate intracellular bacteria. More specifically, genetic fusions to the C-terminus of ClyA, a pore-forming toxin, can be used to create recombinant OMVs for vaccination expressing the antigen of interest on the outside of the OMVs (<xref rid="B153" ref-type="bibr">Rappazzo et&#160;al., 2016</xref>). Interestingly, this strategy produces a Th1/Th17 response in vaccinated mice and was shown to confer protection after vaccination with M2e a potential universal influenza A antigen in a mouse model of influenza, the type of response would also be beneficial for vaccine development to obligate intracellular bacteria (<xref rid="B103" ref-type="bibr">Kim et&#160;al., 2013</xref>; <xref rid="B153" ref-type="bibr">Rappazzo et&#160;al., 2016</xref>). As delivery platforms continue to be developed, the ability to create safe and efficacious vaccines to obligate intracellular bacteria also advances.</p></sec><sec id="s7"><title>Vaccine strategies for intracellular pathogens</title><p>Except for the early WCVs, obligate intracellular bacterial pathogens have thwarted efforts made toward efficacious vaccines. Although most of these obligate intracellular bacteria can be culture <italic toggle="yes">in vitro</italic> the inability to effectively culture axenically like <italic toggle="yes">C. burnetii</italic> has significantly slowed the progress towards the development of safe and efficacious vaccines (<xref rid="B142" ref-type="bibr">Omsland et&#160;al., 2009</xref>; <xref rid="B127" ref-type="bibr">Mcclure et&#160;al., 2017</xref>). This is mainly because genetics and therefore the determination of virulence factors as lagged. It is only the last few years that novel antigen identification platforms have been used for any of the obligate intracellular pathogens. The novel methodologies and machine learning algorithms developed during the Sars-Cov-2 pandemic have made the next phases of antigen discovery imminent. Here we present the current understanding of the immunobiology of key obligate intracellular bacteria including <italic toggle="yes">Rickettsiaceae</italic>, <italic toggle="yes">C. burnetti</italic>, and <italic toggle="yes">Anaplasmataceae</italic> and the current state of vaccine development efforts to this unique group of pathogens. All of the CoPs sections for these bacteria have been determined using animal models or human infections from natural infections and although they have provided groundbreaking information the CoPs for licensing will still need to be defined in the future.</p></sec><sec id="s8"><title>Rickettsiaceae</title><sec id="s8_1"><title>Bacteria and disease overview</title><p>The family <italic toggle="yes">Rickettsiaceae</italic> consists of obligate intracellular bacteria belonging to the genera <italic toggle="yes">Orientia</italic> and <italic toggle="yes">Rickettsia</italic>. These bacteria have a wide range of potential hosts, including humans, which are infected via arthropod vectors (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Lifecycle of arthropod vectors responsible for transmitting tick-borne diseases to humans. Ixodidae are a family of hard ticks responsible for transmitting ehrlichiosis, anaplasmosis, and rickettsioses in a lifecycle involving three-hosts. Adult females detach from a host after feeding to lay eggs. Six-legged larvae hatch from the eggs and seek out a host (often a rodent) to attach and feed. Engorged larvae leave their host and molt into nymphs before seeking out a second host (often a rodent). Nymphs drop from their host and molt into adults before attaching to a third host (often larger mammals, including humans). Adults will feed and mate on the third host before detaching and laying eggs to restart the cycle (1). Chiggers, responsible for spreading scrub typhus, spend most of their life underground. Larvae emerging from infected eggs, start to display host-seeking behavior within a few days by forming clusters on leaves and grass above the soil surface. The larvae feed on a vertebrate host (including humans), becoming engorged and increasing in size by several fold. They then detach and return to a suitable habitat on the soil surface. Over a 2-week period engorged larvae develop into a quiescent 8-legged nymphal phase. A month later, the adult finally emerges and may survive for 15 months or more. When an infected adult lays eggs, <italic toggle="yes">O. tsutsugamushi</italic> is transovarially transmitted to the offspring, maintaining their infectivity over long periods of time and restarting the life cycle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-14-1282183-g002.jpg"/></fig><p>The genus <italic toggle="yes">Orientia</italic> (previously genus <italic toggle="yes">Rickettsia)</italic> was long considered to include only a single species, <italic toggle="yes">O. tsutsugamushi</italic>. <italic toggle="yes">O. tsutsugamushi</italic>, the causative agent of scrub typhus, is an emerging vector-born pathogen transmitted to humans during a blood meal from infected trombiculid mites (chiggers). The geographical distribution of scrub typhus was historically considered to be limited to Asia, Australia, and islands in the Pacific Ocean an area referred to as the Tsutsugamushi triangle (<xref rid="B97" ref-type="bibr">Kelly et&#160;al., 2009</xref>; <xref rid="B59" ref-type="bibr">Elliott et&#160;al., 2019</xref>). However, recent cases of scrub typhus like illness outside the Tsutsugamushi triangle coupled with efforts to broaden molecular surveillance of scrub typhus have revealed evidence of <italic toggle="yes">Orientia</italic> species far outside of the triangle region including cases in Africa, Europe, and South America and resulted the identification of at least two genetically distinct <italic toggle="yes">Orientia</italic> agents, <italic toggle="yes">Candidatus</italic> O. chuto and <italic toggle="yes">Candidatus</italic> O. chiloensis (<xref rid="B92" ref-type="bibr">Jiang and Richards, 2018</xref>). Given the potential severity of scrub typhus infections, a mortality rate of up to 35% if not treated early, and rising concerns over potential outbreaks of scrub typhus in vulnerable regions, efforts to develop effective vaccines have grown in recent years (<xref rid="B33" ref-type="bibr">Chaudhry et&#160;al., 2019</xref>).</p><p>
<italic toggle="yes">Rickettsiae</italic> are a diverse genus of bacteria that can be subdivided into four main groups based on molecular, phylogenetic, and serological profiling. The first two groups are the typhus group (TG) and spotted fever group (SFG), which represent the majority of severe human-acquired rickettsiosis. The TG includes two closely related species: <italic toggle="yes">R. typhi</italic> and <italic toggle="yes">R. prowazekii</italic>, the causative agents of murine typhus and epidemic typhus, respectively. The SFG is more heterogeneous and contains most <italic toggle="yes">Rickettsia species</italic>, approximately 20, including <italic toggle="yes">R. rickettsii</italic> and <italic toggle="yes">R. conorii</italic>, the causative agents of Rocky Mountain Spotted Fever (RMSF) and Mediterranean Spotted Fever, respectively. <italic toggle="yes">R. akari</italic> and <italic toggle="yes">R. felis</italic> belong to the transitional group (TRG), so-called because they consist of features represented by SFG and TG. Finally, there is a non-pathogenic ancestral group (AG) consisting of <italic toggle="yes">R. belii</italic> and <italic toggle="yes">R. canadensis</italic>. While SFG rickettsioses are transmitted to mammals predominantly via ticks, TG and TRG rickettsiae have a much broader arthropod reservoir including fleas, mites, lice, and ticks (<xref rid="B143" ref-type="bibr">Osterloh, 2017</xref>). The geographical range for some of the tick species responsible for transmission of <italic toggle="yes">Rickettsia</italic> has increased in recent years, likely as a result of warmer climates (<xref rid="B95" ref-type="bibr">Karbowiak, 2014</xref>). This in turn has correlated with an increased incidence of rickettsioses not only in endemic regions but also where rickettsioses were rarely documented (<xref rid="B2" ref-type="bibr">Adem, 2019</xref>).</p></sec><sec id="s8_2"><title>CoPs</title><p>During the early stages of infection, rickettsiae invade professional phagocytes in the dermis before spreading to endothelial cells. Here, the bacteria replicate in the cytosol before initiating cell-to-cell spread either by fusing with the host membrane and budding off (<italic toggle="yes">Orientia</italic> spp.), utilizing actin-based motility (SFG), or rupturing the parasitized host cell (TG). Due to the obligate intracellular lifecycle and innate evasion strategies of rickettsiae, seroconversion following infection is significantly delayed (<xref rid="B65" ref-type="bibr">Fournier et&#160;al., 2002</xref>). Diagnostic antibody titers in <italic toggle="yes">R. typhi</italic> and <italic toggle="yes">R. conorii</italic> infected patients do not often develop until around two to three weeks after an initial infection (<xref rid="B51" ref-type="bibr">Dumler et&#160;al., 1991</xref>; <xref rid="B65" ref-type="bibr">Fournier et&#160;al., 2002</xref>). Additionally, a study using inactived <italic toggle="yes">R. rickettsii</italic> lead to a rise in humoral response in a subset of vaccinees but did not prevent disease (<xref rid="B52" ref-type="bibr">Dupont et&#160;al., 1973</xref>). Thus, humoral immunity plays only a minor role in mediating host protection of primary infection but may play a more significant role in limiting secondary infections (<xref rid="B31" ref-type="bibr">Chan et&#160;al., 2010</xref>). During the early stages of a primary infection, antibodies produced in the absence of CD4+ T cell help are less protective than antibodies generated with CD4+ T help. In a study involving convalescent serum from athymic nude mice donors, passive transfer of antibodies was able to confer protection in a euthymic mouse but not an athymic mouse following an <italic toggle="yes">R. akari</italic> infection (<xref rid="B98" ref-type="bibr">Kenyon and Pedersen, 1980</xref>). However, in SCID mice antibodies do protect against <italic toggle="yes">R. conorri</italic> infection (<xref rid="B63" ref-type="bibr">Feng et&#160;al., 2004</xref>). Therefore, antibodies to play a role in mediating protection however cellular immunity is also important.</p><p>In murine and preclinical animals studies cellular immunity is known to play an essential role in protection against rickettsial infections, with both CD4+ and CD8+ T cell-deficient mice demonstrating increased susceptibility to infection with TG, SFG, and <italic toggle="yes">O. tsutsugamushi</italic> (<xref rid="B203" ref-type="bibr">Walker et&#160;al., 2001</xref>; <xref rid="B131" ref-type="bibr">Moderzynski et&#160;al., 2016</xref>; <xref rid="B212" ref-type="bibr">Xu et&#160;al., 2017</xref>). In addition to providing help with B cell production of antibodies, CD4+ T cells release proinflammatory effector molecules, such as IFN&#947; and TNF&#945;, during infection. Both cytokines have been shown to play an important role in host protection from <italic toggle="yes">R. conorii</italic> and <italic toggle="yes">R. typhi</italic> with depletion of either IFN&#947; or TNF&#945; leading to enhanced susceptibility in infected C3H/HeN mice (<xref rid="B61" ref-type="bibr">Feng et&#160;al., 1994</xref>; <xref rid="B131" ref-type="bibr">Moderzynski et&#160;al., 2016</xref>). One of the ways these cytokines influence the outcome of rickettsial infection is by directly acting on macrophages and neutrophils to enhance their bacterial activity by inducing the expression of reactive nitrogen species (<xref rid="B168" ref-type="bibr">Salim et&#160;al., 2016</xref>).</p><p>Given the intracellular replication of rickettsiae, CD8+ T cell-mediated cytotoxic killing of infected cells is required for bacterial clearance. Transgenic mice that lack the cytotoxic T cell potential (C57Bl/6 Perforin -/-) have been shown to demonstrate increased susceptibility and lethality to <italic toggle="yes">R. australis</italic> (TRG) infection compared with both wild-type (WT) and IFN&#947; knock out (KO) mice (<xref rid="B203" ref-type="bibr">Walker et&#160;al., 2001</xref>). However, surprisingly Perforin KO mice in a BALB/c background are equally resistant to <italic toggle="yes">R. typhi</italic> as WT mice (<xref rid="B130" ref-type="bibr">Moderzynski et&#160;al., 2017</xref>). These findings suggest cytotoxic activity might be more important for protection against some species of rickettsiae than others. However, these results are confounded by the different susceptibility of mice to various rickettsiae where BALBc mice are considered resistant (<xref rid="B55" ref-type="bibr">Eisemann et&#160;al., 1984</xref>). These studies and the ones above argue that our strategy to provide a Th1 CD4+ T cell, CD8+ cytotoxic T cell, and pathogen specific antibody response should confer the best protection. Another cytotoxin released by CD8+ T cells is Granzyme B, which triggers caspase-mediated apoptosis of infected cells. During infection with <italic toggle="yes">R. typhi</italic> or <italic toggle="yes">R. conorii</italic>, antigen-experienced CD8+ T cell (CD44<sup>high</sup>) numbers are highest around 7-10 days post-infection (<xref rid="B203" ref-type="bibr">Walker et&#160;al., 2001</xref>; <xref rid="B28" ref-type="bibr">Caro-Gomez et&#160;al., 2014a</xref>). This time point also coincides with the beginning of bacterial clearance from infected tissues at which point effector-like memory CD8+ T cells (CD27<sup>low</sup>CD43<sup>low</sup>) increase their expression of Granzyme B (<xref rid="B28" ref-type="bibr">Caro-Gomez et&#160;al., 2014a</xref>). As with CD4+ T cells, stimulated IFN&#947; release by CD8+ T cells is another strong correlate of protection against rickettsial infections. Mice lacking IFN&#947; (IFN&#947;-/-) or its receptor (IFNGR-/-) often demonstrate enhanced susceptibility to rickettsiosis (<xref rid="B130" ref-type="bibr">Moderzynski et&#160;al., 2017</xref>; <xref rid="B26" ref-type="bibr">Burke et&#160;al., 2021</xref>). Collectively these data suggest that polyfunctional T cells play a vital role in host defense against rickettsial infections.</p><p>Initially, antibody responses were identified as an important component of protection afforded by early <italic toggle="yes">Rickettsia</italic> vaccines based on killed whole cells (<xref rid="B52" ref-type="bibr">Dupont et&#160;al., 1973</xref>; <xref rid="B124" ref-type="bibr">Mason et&#160;al., 1976</xref>; <xref rid="B5" ref-type="bibr">Anacker et&#160;al., 1985</xref>). However, it is now known that antibodies play only a minor role in protection during primary infection and they are not cross-reactive among phylogenetically distant rickettsiae (<xref rid="B62" ref-type="bibr">Feng and Walker, 2003</xref>). In contrast, T cells can mediate cross-protection between distantly related rickettsiae, suggesting T cell-mediated immunity is responsible for long-lasting cross-protective immunity (<xref rid="B28" ref-type="bibr">Caro-Gomez et&#160;al., 2014a</xref>). Thus, T cell antigens should be preferentially considered for inclusion in future vaccines against rickettsiae to provide cross-protection and should be combined with specific B cells antigens identified using the novel techniques described in this review. Identification of novel antibody antigens using bioinformatics and machine-learning may also afford the ability to identify cross-reactive epitopes.</p></sec></sec><sec id="s9"><title>Typhus group vaccines</title><p>The first vaccines against TG rickettsia were developed in the 1920s and pioneered by Polish zoologist Rudolf Weigl. His WCV was produced by isolating the midguts of lice infected with <italic toggle="yes">R. prowazekii</italic>, homogenizing them into a paste, and heat-inactivating (<xref rid="B149" ref-type="bibr">Polak et&#160;al., 2022</xref>). A total of 30-100 lice were required to produce a single vaccine dose, which provided significant protection in a guinea pig model of infection. His vaccine was later appropriated by the Nazi Party of Germany and used to immunize German soldiers during World War II. However, Weigl is credited with intentionally reducing the efficacy of vaccine doses destined for German soldiers and secretly delivering thousands of doses to Jewish prisoners in ghettos and concentration camps across Poland. Similar WCV derivatives were prepared from isolating <italic toggle="yes">R. prowazekii</italic> from infected rabbit lungs or propagated in yolk sacs (Cox vaccine) before formalin inactivation (<xref rid="B202" ref-type="bibr">Walker, 2009</xref>). However, inactivated WCVs were only capable of reducing the severity and duration of disease rather than preventing infection (<xref rid="B52" ref-type="bibr">Dupont et&#160;al., 1973</xref>). Additionally, there were concerns over the safety of these vaccines due to adverse reactions at the injection site and hypersensitivity to yolk-sacs. The adverse reactions were eliminated in humans by preparing the formalin inactivated WCV in chicken or duck embryo cell culture and showed better protection in animal models however this vaccine was never licensed (<xref rid="B99" ref-type="bibr">Kenyon et&#160;al., 1975</xref>; <xref rid="B8" ref-type="bibr">Ascher et&#160;al., 1978</xref>). It is our opinion that WCVs will not provide the best protection because they are not efficient at stimulating CD8+ cytotoxic T cell responses.</p><p>Inactivated WCVs were eventually replaced by live attenuated vaccines. In the 1930s, an attenuated strain of <italic toggle="yes">R. typhi</italic> (Casablanca) was created by isolating bacteria from infected guinea pig tissues and treating them with 5% ox bile (previously used in an attenuated dengue vaccine). The resulting vaccine provided heterologous protection against <italic toggle="yes">R. typhi</italic> and <italic toggle="yes">R. prowazekii</italic> (<xref rid="B53" ref-type="bibr">Dyer, 1943</xref>). However, differences in bacterial tissue burden between infected animals led to issues regarding quality control and batch-to-batch variation. One of the most successful live attenuated vaccines against TG rickettsia comes from the <italic toggle="yes">R. prowazekii</italic> Madrid strain. Originally termed Madrid 1 after a patient who died from typhus in Madrid during 1941 epidemic, the strain was passaged 11 times through chick embryos and was renamed Madrid E (<xref rid="B157" ref-type="bibr">Richards, 2004</xref>). Avirulence of <italic toggle="yes">R. prowazekii</italic> Madrid E is maintained by a mutation in the methyltransferase responsible for methylation of surface proteins (<xref rid="B204" ref-type="bibr">Wei-Mei et&#160;al., 1992</xref>). The vaccine was originally purified from desiccated yolk-sacs and was demonstrated to elicit protection in guinea pigs without resulting in any recoverable bacteria. Clinical studies of <italic toggle="yes">R. prowazekii</italic> Madrid E strain demonstrated robust immunity against virulent <italic toggle="yes">R. prowazekii</italic> Naples and Breinl strains that lasted at least 5 years post-immunization (<xref rid="B66" ref-type="bibr">Fox, 1955</xref>). Several years later it was determined that some adverse reactions were likely a result of yolk-sac contaminants and endotoxin, so modifications were made to the manufacturing. The Madrid E vaccine is no longer in use due to the persistence of some adverse events, uncertainty over the mechanism and stability of attenuation, and concerns over the potential for unrestricted growth in immunocompromised individuals (<xref rid="B218" ref-type="bibr">Zhang et&#160;al., 2006</xref>).</p><p>Most subunit vaccine candidates against rickettsiae are surface-exposed antigens recognized by antibodies to enhance bacterial uptake into phagocytes. However, given the significance of cellular immunity in host protection from rickettsial disease, efforts to identify vaccine candidates have focused on discrete antigens that trigger T cell engagement. Although very few rickettsial antigens have been identified, the most promising belong to the surface cell antigen autotransporter family (Sca 0-5) involved in bacterial adherence and cell uptake. Of particular interest is outer membrane protein B (OmpB/Sca5), which is recognized by convalescent serum from laboratory animals and patients previously infected with <italic toggle="yes">R. typhi</italic> (<xref rid="B44" ref-type="bibr">Dasch and Bourgeois, 1981</xref>). Additionally, T cells from <italic toggle="yes">R. typhi</italic> infected patients secrete IL-2 and IFN&#947; in response to macrophages expressing fragments of <italic toggle="yes">R. rickettsii</italic> OmpB, suggesting recognition of peptides presented by MHCI by CD8+ T cells and cross-reactivity of T cells to conserved OmpB epitopes between TG and SFG rickettsiae (<xref rid="B54" ref-type="bibr">Dzul-Rosado et&#160;al., 2017</xref>). Guinea pigs vaccinated with OmpB from <italic toggle="yes">R. typhi</italic> are protected from homologous challenge (<xref rid="B45" ref-type="bibr">Dasch et&#160;al., 1984</xref>).</p><p>Using a reverse vaccinology approach, Caro-Gomez et&#160;al. identified a collection of novel antigens (RP403, RP598, RP739, and RP778) from <italic toggle="yes">R. prowazekii</italic> based on the presence of CD8+ T cell epitopes (<xref rid="B29" ref-type="bibr">Caro-Gomez et&#160;al., 2014b</xref>). These antigens were recombinantly expressed in SCEV 4-10 cells for presentation by MHCI and were then used to immunize C3H/HeN mice. Immunization resulted in an antigen-specific CD8+ T cell response that produced IFN&#947; and granzyme B, which protected mice from a lethal heterologous challenge with <italic toggle="yes">R. typhi</italic> (<xref rid="B28" ref-type="bibr">Caro-Gomez et&#160;al., 2014a</xref>). We hope that novel strategies to identify B and T cells antigens developed during the Sars-Cov-2 pandemic are used to further identify potentially protective epitopes.</p></sec><sec id="s10"><title>Spotted fever group vaccines</title><p>Like the first TG vaccines, early SFG vaccines consisted of fixed WCV material. In 1925, Spencer and Parker prepared the first RMSF vaccine by isolating <italic toggle="yes">R. rickettsii</italic> from the intestines of infected ticks and inactivating the material in phenol (<xref rid="B180" ref-type="bibr">Spencer and Parker, 1925</xref>). While two doses of this vaccine were able to elicit strong protection in rhesus macaques, the vaccine was only able to reduce the severity of illness in humans rather than prevent infection. Subsequent phenol and formalin-treated suspensions of <italic toggle="yes">R. ricketsii</italic> from yolk sacs (Cox method) were produced but they were only effective at delaying the onset of symptoms and shortening the duration of illness. Improvements to SFG vaccines were eventually made using <italic toggle="yes">R. rickettsii</italic> cultures grown in chick embryo fibroblasts and purified by sucrose gradient. We again postulate that WCVs will not be protection because they are not efficient at stimulating CD8+ cytotoxic T cell responses.</p><p>Of the SFG immunogens identified experimentally, outer membrane proteins A (OmpA/Sca0) and B (OmpB/Sca5) have been studied most. Immunization of guinea pigs with recombinant OmpA from <italic toggle="yes">R. rickettsii</italic> has been shown to elicit strong protection from homologous challenge and partial protection from heterologous <italic toggle="yes">R. conorii</italic> challenge (<xref rid="B199" ref-type="bibr">Vishwanath et&#160;al., 1990</xref>). DNA vaccination using fragments of OmpA (OmpA703&#8211;1288, OmpA755&#8211;1301 or OmpA980&#8211;1301 or OmpA1644&#8211;2213) or OmpB (OmpB451&#8211;846 or OmpB754&#8211;1308) from <italic toggle="yes">R. conorii</italic> have also been used for immunization. A priming dose using plasmid DNA followed by boost immunization with the corresponding recombinant peptide induced a significant IFN&#947; response in T cells upon <italic toggle="yes">in vitro</italic> recall with <italic toggle="yes">R. conorii</italic> WCV. This boosting strategy was also successful in protecting mice from lethal challenge with <italic toggle="yes">R. conorii</italic> (<xref rid="B41" ref-type="bibr">Crocquet-Valdes et&#160;al., 2001</xref>). Interestingly, heterologous DNA immunization with plasmids encoding fragments of OmpA and OmpB (OmpA703&#8211;1288 or OmpA1644&#8211;2213 with OmpB451&#8211;846 or OmpB754&#8211;1308) was also protective against lethal challenge with <italic toggle="yes">R. conorii</italic> and shown to be more immunogenic than either vaccine alone (<xref rid="B50" ref-type="bibr">D&#237;az-Montero et&#160;al., 2001</xref>). Antibodies likely play a significant role in OmpA/B mediated protection given passive immunization of antigen-specific antibodies into guinea pigs and immunodeficient SCID mice protects animals from a lethal <italic toggle="yes">R. rickettsii</italic> challenge (<xref rid="B63" ref-type="bibr">Feng et&#160;al., 2004</xref>). Additionally, OmpA/B specific antibodies have been shown to facilitate opsonophagocytosis of <italic toggle="yes">R. conorii</italic>, inhibit adherence of <italic toggle="yes">R. rickettsii</italic> to host cells, and mediate complement-dependent killing of SFG rickettsia. Each of these antibody-mediated mechanisms may contribute to protection against infection.</p><p>Another antigen of interest is YbgF, a Tol-Pal system protein identified as a major seroreactive surface exposed protein (<xref rid="B152" ref-type="bibr">Qi et&#160;al., 2013b</xref>). Immunizing C3H/HeN mice with recombinant YbgF resulted in the proliferation of IFN&#947; secreting CD4+ and CD8+ T cells and fewer bacteria in the spleen, liver, and lungs following infection with <italic toggle="yes">R. rickettsia</italic> (<xref rid="B73" ref-type="bibr">Gong et&#160;al., 2015a</xref>). Similarly, C3H/HeN mice immunized with recombinant YbgF from <italic toggle="yes">R. heilongjiangensis</italic> (the causative agent of Far-Eastern Spotted Fever; FESF) results in a CD4+ T cell response that limits the bacterial burden upon infection with homologous bacteria (<xref rid="B151" ref-type="bibr">Qi et&#160;al., 2013a</xref>). Vaccination with another component of the <italic toggle="yes">R. rickettsii</italic> Tol-Pal system, TolC, was also shown to be immunogenic but less efficient at restricting rickettsial burden and impairment in the spleen, liver, and lungs than YbgF (<xref rid="B73" ref-type="bibr">Gong et&#160;al., 2015a</xref>).</p><p>Other immunogenic proteins that have been used for experimental vaccination against SFG rickettsiae include Adr1, Adr2, OmpW, and Porin-4. C3H/HeN mice immunized with recombinant Adr1, OmpW, or Porin-4 lead to a reduced bacterial burden in tissues upon challenge with <italic toggle="yes">R. rickettsia</italic> (<xref rid="B75" ref-type="bibr">Gong et&#160;al., 2014a</xref>). Similarly, immunization with recombinant Adr2 protects mice from <italic toggle="yes">R. rickettsii</italic> infection and leads to enhanced production of IFN&#947; by CD4+ T cells and TNF&#945; by CD8+ T cells (<xref rid="B76" ref-type="bibr">Gong et&#160;al., 2014b</xref>). <italic toggle="yes">In vitro</italic> neutralization assays revealed that sera from mice immunized with recombinant Adr1, Adr2, or OmpW reduced <italic toggle="yes">R. rickettsii</italic> adherence to and invasion of vascular endothelial cells. In many instances, combination vaccines provide the most promising outcome from infection. One such example is a combination of recombinant Adr2 with OmpB, which results in enhanced protection against <italic toggle="yes">R. rickettsii</italic> infection than either one alone, resulting in a stronger IFN&#947; response and fewer detectable bacteria (<xref rid="B74" ref-type="bibr">Gong et&#160;al., 2015b</xref>).</p></sec><sec id="s11"><title>
<italic toggle="yes">Orientia</italic> spp. vaccines</title><p>Early <italic toggle="yes">O. tsutsugamushi</italic> vaccines were WCV derivatives purified from the lungs of infected cotton rats and fixed in formalin. The protection provided by this vaccine in humans was initially based on 15 out of 16 individuals developing mild disease, which led to large-scale production of the vaccine towards the end of World War II (<xref rid="B201" ref-type="bibr">Walker, 1947</xref>). Similarly, studies with this vaccine showed it provided only partial protection of mice against infection, resulting in a milder disease outcome (<xref rid="B9" ref-type="bibr">Bailey et&#160;al., 1948</xref>). A human field study performed later in Japan showed that there was no demonstrable protection afforded by this vaccine (<xref rid="B17" ref-type="bibr">Berge et&#160;al., 1949</xref>). One of the drawbacks to using formalin-inactivated vaccines is antigen modifications resulting from formalin cross-linking. An alternative approach using gamma-irradiated <italic toggle="yes">O. tsutsugamushi</italic> was found to protect mice against a lethal challenge with a homologous strain over 12 months (<xref rid="B58" ref-type="bibr">Eisenberg George and Osterman Joseph, 1978</xref>). However, protection against heterologous strains appeared to wane rapidly and was not significant after 6 months.</p><p>Strain diversity among <italic toggle="yes">O. tsutsugamushi</italic> is one of the biggest challenges to vaccine development, as noted by cases of reinfection and the lack of serological cross-reactivity in human cases (<xref rid="B146" ref-type="bibr">Philip, 1948</xref>; <xref rid="B108" ref-type="bibr">Kuwata, 1952</xref>). Sequence analysis of known immunodominant antigens, including type-specific antigen (TSA) 56 and surface cell antigens (<italic toggle="yes">sca</italic>), has shown variable homology and levels of conservation among different <italic toggle="yes">O. tsutsugamushi</italic> strains (<xref rid="B164" ref-type="bibr">Ruang-Areerate et&#160;al., 2011</xref>; <xref rid="B80" ref-type="bibr">Ha et&#160;al., 2012</xref>). Furthermore, comparative genomics of two <italic toggle="yes">O. tsutsugamushi</italic> strains (Boryong and Ikeda) revealed a common set of repetitive sequences that have been explosively amplified in both genomes, which resulted in extensive genome shuffling as well as duplications and deletions of many genes. Consequently, natural infection with <italic toggle="yes">O. tsutsugamushi</italic> does not provide long-term protection from reinfection, particularly from different strains. In a human trial involving individuals previously infected with scrub typhus, reinfection with <italic toggle="yes">O. tsutsugamushi</italic> resulted&#160;in a similar severity of illness compared to na&#239;ve controls (<xref rid="B177" ref-type="bibr">Smadel et&#160;al., 1950</xref>). The original strain responsible for infection in most of the volunteers was believed to have been different from the one used in the study (Gilliam) and was therefore likely a heterologous challenge. However, for one of the volunteers it was known that the original infection, 3 years prior, was caused by <italic toggle="yes">O. tsutsugamushi</italic> Gilliam and this individual developed no other symptoms besides erythema at the site of inoculation. In this instance, heterologous immunity may be very short-lived while homologous immunity may last longer.</p><p>Characterization of <italic toggle="yes">O. tsutsugamushi</italic> immunodominant antigens by reactive convalescent serum with bacterial lysates revealed five major proteins were common to three strains (<xref rid="B56" ref-type="bibr">Eisemann and Osterman, 1981</xref>). They were identified as TSA 22, 47, 56, 58, and 110 based on their molecular weight. Of these five antigens, TSA56 has been regarded as one of the more favorable vaccine targets due to conserved epitopes among different strains of <italic toggle="yes">O. tsutsugamushi</italic> and its role in the attachment and invasion of host cells (<xref rid="B37" ref-type="bibr">Cho et&#160;al., 2010</xref>). Mice immunized with TSA56 not only generate a robust humoral response, including neutralizing antibodies, but elevated IFN&#947; and IL-2 production, associated with T cells. These mice were also shown to have measurable protection against a homologous challenge with <italic toggle="yes">O. tsutsugamushi</italic> Boryong strain (<xref rid="B39" ref-type="bibr">Choi et&#160;al., 2014</xref>). Furthermore, a novel recombinant antigen comprised of conserved regions of TSA56 was shown to elicit protection against both homologous and heterologous lethal challenges (<xref rid="B102" ref-type="bibr">Kim et&#160;al., 2019</xref>). The authors also demonstrated protective immunity could be adoptively transferred using CD4+ or CD8+ T cells from immunized mice, whereas immune B cells failed to do so. Thus, providing further evidence of the importance cellular immunity against conserved epitopes plays in protective immunity against scrub typhus. Other successful studies demonstrating a protective role of TSA56 include a fusion with maltose-binding protein (MBP) and a truncated version (r56). In both instances, immunized mice exhibited high titer antigen-specific antibodies and cellular immune responses that resulted in protection from a homologous, but not heterologous lethal challenge (<xref rid="B173" ref-type="bibr">Seong et&#160;al., 1997</xref>; <xref rid="B32" ref-type="bibr">Chattopadhyay and Richards, 2007</xref>).</p><p>The TSA47 outer membrane protein is another major antigen that has been considered for vaccination. Polyclonal T cells derived from infected mice are highly stimulated in the presence of TSA47 and antigen-specific antibodies are cross-reactive with at least 8 different strains of <italic toggle="yes">O. tsutsugamushi</italic> (<xref rid="B138" ref-type="bibr">Oaks et&#160;al., 1989</xref>; <xref rid="B84" ref-type="bibr">Hickman et&#160;al., 1993</xref>). Upon immunizing mice with a DNA construct containing TSA47, outbred CD-1 mice were found to produce polyfunctional splenocytes secreting IFN&#947;, IL-4, and IL-13 in addition to a strong antibody response (<xref rid="B32" ref-type="bibr">Chattopadhyay and Richards, 2007</xref>). In challenge studies using TSA47 as the immunizing antigen delivered intranasally, mice developed high antibody titers, including IgG and IgA in bronchoalveolar lavage (BAL) fluid, as well as cellular immunity correlative with a Th1 response (<xref rid="B38" ref-type="bibr">Choi et&#160;al., 2017</xref>; <xref rid="B144" ref-type="bibr">Park et&#160;al., 2021</xref>). In both studies, mice were significantly protected against a lethal challenge with <italic toggle="yes">O. tsutsugamushi</italic> Boryong. A fusion protein of TSA47 with TSA56 from <italic toggle="yes">O. tsutsugamushi</italic> Karp was evaluated for its efficacy in protecting mice against a homologous challenge. In this study, the fusion protein was found to provide greater protection than when either protein was given individually (<xref rid="B215" ref-type="bibr">Yu et&#160;al., 2005</xref>). However, protection was only partial (50%) and the efficacy of a TSA47-56 fusion protein against heterologous challenge remains to be determined.</p><p>Other immunogenic proteins of interest from <italic toggle="yes">O. tsutsugamushi</italic> are the autotransporter proteins ScaA, ScaC, ScaD, and ScaE. Each of these antigens has been shown to cross-react with convalescent serum with ScaA identified as the most reactive (<xref rid="B80" ref-type="bibr">Ha et&#160;al., 2012</xref>). Immunizing mice with ScaA resulted in enhanced protection against both homologous (Boryong strain) and heterologous (Karp and Kato strains) <italic toggle="yes">O. tsutsugamushi</italic> challenge when combined with TSA56 (<xref rid="B81" ref-type="bibr">Ha et&#160;al., 2015</xref>). In a separate study from the same group, ScaA was coupled to zinc oxide nanoparticles that were taken up by DCs <italic toggle="yes">in vitro</italic> and induced protective immunity in mice. Immunized mice developed antibodies against ScaA as well as IFN&#947; producing CD4+ and CD8+ T cells.</p><p>Given that natural immunity to <italic toggle="yes">O. tsutsugamushi</italic> wanes over time and there is significant antigenic diversity among strains, it is likely any successful vaccine against scrub typhus will need to overcome these challenges. Currently, the number of antigens identified as potential <italic toggle="yes">O. tsutsugamushi</italic> vaccine targets remains limited, and further studies will need to rely on identifying antigens based on T cell epitopes in addition antibody cross-reactivity. Antigens that elicit strong cellular responses, including IFN&#947; secreting CD4+ and CD8+ T cells, are likely necessary for protection against rickettsial diseases. Memory cells that have a bimodal distribution consisting of both effector memory and central memory phenotypes will help to overcome issues of waning immunity. Lastly, vaccines containing fusion proteins or combinations of multiple antigens are likely to improve the breadth of immunity across different strains to support heterologous protection, however, it is unknown how many fusion partners will be needed. Again, we hope that novel strategies to identify B and T cells antigens developed during the Sars-Cov-2 pandemic are used to further identify potentially protective epitopes.</p></sec><sec id="s12"><title>C. burnetii</title><sec id="s12_1"><title>Bacteria and disease overview</title><p>
<italic toggle="yes">C. burnetii</italic> is a Gram-negative obligate intracellular bacterium and the causative agent of the zoonotic disease query fever (Q fever) (<xref rid="B196" ref-type="bibr">Van Schaik et&#160;al., 2013</xref>). Q fever can present either as an acute self-limiting febrile disease or as a chronic disease most commonly associate with endocarditis (<xref rid="B125" ref-type="bibr">Maurin and Raoult, 1999</xref>). Transmission usually occurs after the inhalation of contaminated aerosols. Once inside the lungs <italic toggle="yes">C. burentii</italic> are taken up by alveolar macrophages where they grow and divide in a compartment like a lysosome termed the <italic toggle="yes">Coxiella</italic>-containing vacuole (CCV). <italic toggle="yes">C. burnetii</italic> is listed as a Category B select agent and therefore a safe and efficacious vaccine should be developed.</p></sec><sec id="s12_2"><title>CoPs</title><p>Understanding the mechanisms of immunity to <italic toggle="yes">C. burnetii</italic> can guide the development of protective vaccines against this pathogen. Evaluation of adaptive immune responses after infection or vaccination in humans and laboratory animals indicates that while both cellular and humoral immune responses play a role in protection, cell-mediated immunity is essential for resolution of infection. Humans with acute Q fever develop serum IgM, IgG, and IgA titers against <italic toggle="yes">C. burnetii</italic> antigens that persist for long periods after resolution of infection, while those with chronic Q fever have very high phase I IgG and significantly lower phase II IgM titers (<xref rid="B211" ref-type="bibr">Worswick and Marmion, 1985</xref>; <xref rid="B25" ref-type="bibr">Buijs et&#160;al., 2021</xref>). In mice, experiments using adoptive transfer of immune serum show that serum IgG provides some protection against infection but does not fully control bacterial dissemination and growth. Comparisons of the humoral responses to protective phase I WCVs and non-protective phase II WCVs in mice indicate that IgG targeting phase I lipopolysaccharide may play a significant role in protection against <italic toggle="yes">C. burnetii</italic> (<xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>). <italic toggle="yes">C. burnetii</italic> phase I LPS has been shown to shield surface antigens from antibody binding through steric hindrance, prevent dendritic cell activation by blocking toll-like receptor (TLR) ligands, and resist complement-mediated serum killing (<xref rid="B82" ref-type="bibr">Hackstadt, 1988</xref>; <xref rid="B198" ref-type="bibr">Vishwanath and Hackstadt, 1988</xref>; <xref rid="B175" ref-type="bibr">Shannon et&#160;al., 2005</xref>). Abinanti and Marmion showed that treating <italic toggle="yes">C. burnetii</italic> with immune serum from rabbits exposed to phase I <italic toggle="yes">C. burnetii</italic>, but not serum from rabbits exposed to phase II, inhibited infection in mice (<xref rid="B1" ref-type="bibr">Abinanti and Marmion, 1957</xref>). <italic toggle="yes">In vitro</italic> experiments showed that treatment of <italic toggle="yes">C. burnetii</italic> with serum containing anti-<italic toggle="yes">C. burnetii</italic> IgG potentiates phagocytosis and destruction of bacteria by macrophages <italic toggle="yes">in vitro</italic> (<xref rid="B105" ref-type="bibr">Kishimoto and Walker, 1976</xref>). However, the adoptive transfer of immune serum into T cell-deficient, athymic mice had no significant impact on infection compared to mice receiving non-immune serum, indicating that T cell-mediated immunity is essential for the control of <italic toggle="yes">C. burnetii</italic> infection (<xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>).</p><p>The role of cell-mediated immunity has been evaluated in both humans and laboratory animals. Measurements of the index of lymphoproliferative response, a measure of lymphocyte proliferation upon exposure to an antigen, in humans after vaccination with a WCV showed positive LSI in 85-95% of vaccinees, while only 35-70% showed positive serum antibody titers against <italic toggle="yes">C. burnetii</italic> (<xref rid="B90" ref-type="bibr">Izzo et&#160;al., 1988</xref>). In mice, depletion of T cells results in an inability to control pulmonary infection with <italic toggle="yes">C. burnetii</italic> (<xref rid="B155" ref-type="bibr">Read et&#160;al., 2010</xref>). However, both CD4+ and CD8+ T cells appear to play a role in immunity to <italic toggle="yes">C. burnetii</italic> as immunodeficient mice lacking T cells reconstituted with either CD4+ or CD8+ T cells can control infection (<xref rid="B155" ref-type="bibr">Read et&#160;al., 2010</xref>).</p><p>CD4+ T cells activated through antigen-presentation on MHCII produce IFN&#947; which enhances phagocytosis and production of reactive oxygen species and reactive nitrogen species by macrophages which are an important target cell of <italic toggle="yes">C. burnetii</italic> infection (<xref rid="B6" ref-type="bibr">Andoh et&#160;al., 2007</xref>). <italic toggle="yes">In vitro</italic> stimulation of infected monocytes with IFN&#947; inhibits intracellular <italic toggle="yes">C. burnetii</italic> replication and survival and induces apoptosis (<xref rid="B49" ref-type="bibr">Dellacasagrande et&#160;al., 1999</xref>). CD4+ T cells appear to play an important role in the control of <italic toggle="yes">C. burnetii</italic> replication, however, <italic toggle="yes">in vivo</italic> mouse studies suggest that CD8+ T cells play a larger role in bacterial clearance. In MHCI and MHCII knock-out (KO) mice, MHCII KO mice infected with <italic toggle="yes">C. burnetii</italic> can clear infection, MHCI KO mice develop persistent infections (<xref rid="B27" ref-type="bibr">Buttrum et&#160;al., 2018</xref>). The role of CD8+ T cells in the control of <italic toggle="yes">C. burnetii</italic> infection is not fully understood, however, perforin may be an important mediator of protection as perforin-deficient mice develop significantly more severe splenomegaly than wild-type mice during challenge (<xref rid="B27" ref-type="bibr">Buttrum et&#160;al., 2018</xref>). Overall, an effective vaccine for <italic toggle="yes">C. burnetii</italic> will likely need to produce strong cell-mediated memory from both CD4+ and CD8+ T cells to control intracellular replication and bacterial clearance as well as humoral immunity to enhance vaccine efficacy by neutralizing bacteria before infection of host cells. The current WCVs for <italic toggle="yes">C. burnetii</italic> fail to elicit CD8+ T cell responses and therefore could be improved upon using strategies described in this review.</p></sec></sec><sec id="s13"><title>Current vaccine strategies WVC</title><p>
<italic toggle="yes">C. burnetii</italic> is an obligate intracellular bacterium that is endemic worldwide except for New Zealand and Antarctica and is maintained by persistent infection in sheep, goats, cattle, and camelids, making elimination from the environment extremely difficult (<xref rid="B85" ref-type="bibr">Hilbink et&#160;al., 1993</xref>; <xref rid="B196" ref-type="bibr">Van Schaik et&#160;al., 2013</xref>). Because of this, an effective vaccination program is considered essential to reduce the rate of human infections. Although abbatoir workers, farmers, and veterinary professionals working closely with these domestic species are considered at the greatest risk of infection, interest in the development of vaccines against Q fever was initially driven by concern for the protection of military troops. Some of the first isolates of <italic toggle="yes">C. burnetii</italic> were collected from American soldiers who were infected during their deployment to Italy during World War II. To isolate the bacterium, blood samples from infected patients were inoculated into guinea pigs and then cultured in embryonated yolk sacs. This work produced several strains of <italic toggle="yes">C. burnetii</italic> including the Henzerling strain which was later used for the production of the first formalin-inactivated WCV (<xref rid="B159" ref-type="bibr">Robbins and Rustigian, 1946</xref>; <xref rid="B178" ref-type="bibr">Snyder et&#160;al., 1947</xref>).</p><p>Early evaluation of this WCV in a guinea pig model of infection showed that it reduced mortality to less than 2% in vaccinated animals compared to 40-80% in the unvaccinated group (<xref rid="B178" ref-type="bibr">Snyder et&#160;al., 1947</xref>). Administration of this vaccine in humans showed similarly high levels of protection. An 18-month survey of abattoir workers in southern Australia reported no cases of Q fever among 924 workers vaccinated with a single dose of the formalin-inactivated, Henzerling strain phase I vaccine compared to 34 cases in 1349 unvaccinated (control) workers (<xref rid="B121" ref-type="bibr">Marmion et&#160;al., 1984</xref>). However, early experiments in humans and animals noted local and systemic reactions occurred in some vaccinated individuals (<xref rid="B178" ref-type="bibr">Snyder et&#160;al., 1947</xref>). These reactogenic responses would continue to be a major barrier to the widespread use of the WCV.</p><p>There are currently two licensed formalin-inactivated, WCVs against <italic toggle="yes">C. burnetii</italic>: Q-VAX<sup>&#174;</sup> (Seqirus, Australia) and Coxevac<sup>&#174;</sup> (CEVA Saint&#233; Animale, France), administered to humans and ruminants, respectively. Q-VAX<sup>&#174;</sup> was developed using the phase I Henzerling strain of <italic toggle="yes">C. burnetii</italic> in response to the high rate of infections among abattoir workers in Australia and is only licensed for human use in that country. Clinical trials of Q-VAX<sup>&#174;</sup> and later retrospective studies showed long-lasting protection of greater than 90% 5 years after vaccination (<xref rid="B122" ref-type="bibr">Marmion et&#160;al., 1990</xref>; <xref rid="B210" ref-type="bibr">Woldeyohannes et&#160;al., 2020</xref>). Additionally, the implementation of a vaccination program in Australia in 2002 reduced the incidence of Q fever between 2002 and 2006 by over 50% (<xref rid="B70" ref-type="bibr">Gidding et&#160;al., 2009</xref>). Coxevac&#174; is similarly a whole cell, formalin-inactivated vaccine derived from the phase I Nine Mile strain and licensed for use in ruminants in Europe. Although Coxevac does not significantly reduce infection rates in ruminants, this vaccine has been shown to lower abortion rates in infected animals and reduce exposure risk to humans by decreasing bacterial shedding through vaginal fluids, feces, and milk (<xref rid="B162" ref-type="bibr">Rousset et&#160;al., 2009</xref>; <xref rid="B46" ref-type="bibr">De Cremoux et&#160;al., 2012</xref>).</p><p>Inactivated WCVs against <italic toggle="yes">C. burnetii</italic> are proven to be highly effective at reducing infections in humans, but the high rates of local and systemic reactions after vaccination have prevented widespread licensure of this vaccine (<xref rid="B69" ref-type="bibr">Fratzke et&#160;al., 2022</xref>). Even in early experiments, local induration, erythema, and chronic granulomas with abscesses at the vaccine site were common, and systemic symptoms such as fever, malaise, and anorexia were frequently reported in vaccinated humans with a history of prior exposure to <italic toggle="yes">C. burnetii</italic> (<xref rid="B178" ref-type="bibr">Snyder et&#160;al., 1947</xref>). Injection site granulomas from the WCV may last for weeks to months and occasionally require surgical excision to resolve (<xref rid="B16" ref-type="bibr">Bell et&#160;al., 1964</xref>). Similar local reactions to <italic toggle="yes">C. burnetii</italic> WCVs have been reported in ruminants, rabbits, and guinea pigs (<xref rid="B18" ref-type="bibr">Biberstein et&#160;al., 1974</xref>). To reduce severe reactions to the WCV, humans receiving Q-VAX<sup>&#174;</sup> must undergo pre-vaccination screening which includes measuring anti-<italic toggle="yes">C. burnetii</italic> antibody titers in serum and intradermal sensitivity testing. This intradermal skin test uses a very low dose of whole cell material injected into the skin, and then local induration and erythema are measured 48 hours later, similar to the tuberculin test for Mycobacteriosis (<xref rid="B109" ref-type="bibr">Lackman et&#160;al., 1962</xref>). Despite this pre-vaccination screening strategy, adverse responses to the whole-cell vaccine are still common, with local and systemic reactions reported in 98% and 60% of seronegative, skin test-negative veterinary students, respectively, in a 2018 survey (<xref rid="B172" ref-type="bibr">Sellens et&#160;al., 2018</xref>).</p><p>The pathogenesis and underlying cause of <italic toggle="yes">C. burnetii</italic> WCV reactogenicity are poorly understood. Some early research speculated that phase I LPS is the cause of local reactogenic responses, but more recent studies have disproven this hypothesis (<xref rid="B96" ref-type="bibr">Kaz&#225;r et&#160;al., 1982</xref>; <xref rid="B113" ref-type="bibr">Long et&#160;al., 2021</xref>; <xref rid="B68" ref-type="bibr">Fratzke et&#160;al., 2021b</xref>). These local and systemic reactions are more frequent and severe in individuals with antibody titers against <italic toggle="yes">C. burnetii</italic> from prior exposure and histopathologic evaluation of vaccine site reactions show infiltration of macrophages, neutrophils, and lymphocytes with central abscesses suggesting that <italic toggle="yes">C. burnetii</italic> WCV reactions are a granulomatous type IV hypersensitivity response (<xref rid="B16" ref-type="bibr">Bell et&#160;al., 1964</xref>; <xref rid="B96" ref-type="bibr">Kaz&#225;r et&#160;al., 1982</xref>; <xref rid="B205" ref-type="bibr">Wilhelmsen and Waag, 2000</xref>). Type IV hypersensitivities have a delayed onset and are driven by memory CD4+ and CD8+ T cells. Recently, (<xref rid="B67" ref-type="bibr">Fratzke et&#160;al., 2021a</xref>) showed that in sensitized mice, local and systemic reactions to the whole-cell vaccine are characterized by an increase in IFN&#947; and IL17a+ CD4+ T cells, indicating a Th1/Th17-mediated hypersensitivity (<xref rid="B67" ref-type="bibr">Fratzke et&#160;al., 2021a</xref>) (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref>). However, research into the mechanisms behind the efficacy of the WCV suggest that while anti-<italic toggle="yes">C. burnetii</italic> antibodies provide some immunity, T cell-mediated immune memory is critical for vaccine-induced protection against infection (<xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>). Thus, novel vaccine strategies against <italic toggle="yes">C. burnetii</italic> must provide a balanced immune response to maintain protective immunity while reducing adverse reactions.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Delayed Type Hypersensitivity Response in the Mouse Model. SKH1 mice were infected with <italic toggle="yes">C. burentii</italic> and then the infection was resolved before WVC prepared from NMI was injected intramuscularly. The skin sections were removed 2 weeks later and sent for H&amp;E staining. This is a representative image. A central abscess (arrow) surrounded by lymphohistiocytic inflammation (arrowheads) within the subcutaneous tissue. Hematoxylin and eosin, 4x magnification, bar=200 &#181;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-14-1282183-g003.jpg"/></fig></sec><sec id="s14"><title>Early alternatives to the <italic toggle="yes">C. burnetii</italic> WCV</title><p>Several alternative <italic toggle="yes">C. burnetii</italic> vaccines have been tested over the decades since the development of the WCV, including phase II inactivated, modified live, and solubilized and residual antigen vaccines (<xref rid="B160" ref-type="bibr">Robinson and Hasty, 1974</xref>; <xref rid="B96" ref-type="bibr">Kaz&#225;r et&#160;al., 1982</xref>; <xref rid="B208" ref-type="bibr">Williams et&#160;al., 1992</xref>; <xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>). Serial passages of <italic toggle="yes">C. burnetii</italic> through embryonated yolk sacs results in attenuation of the bacteria, termed phase variation. A large chromosomal deletion occurs during this passage resulting in the truncation of the LPS (<xref rid="B15" ref-type="bibr">Beare et&#160;al., 2018</xref>). Phase I <italic toggle="yes">C. burnetii</italic>, isolated from infected animals or humans, is highly virulent and infectious while the phase II form, isolated after multiple passages through embryonated yolk sacs, shows a marked reduction in infectivity except in immunocompromised humans and animals (<xref rid="B195" ref-type="bibr">Van Schaik et&#160;al., 2017</xref>). This makes phase II <italic toggle="yes">C. burnetii</italic> much safer to manufacture for use in vaccines and allows for work under biosafety level 2 conditions instead of the high containment required for phase I bacteria. However, a formalin-inactivated, WCV derived from phase II <italic toggle="yes">C. burnetii</italic> produces a marked reduction in protective efficacy compared to phase I-derived vaccines (<xref rid="B182" ref-type="bibr">Stoker and Fiset, 1956</xref>). This phase variation was later determined to be due to alteration in the LPS expressed on the surface of <italic toggle="yes">C. burnetii</italic> and later studies showed that phase I LPS is an essential component for the efficacy of the WCV (<xref rid="B170" ref-type="bibr">Schramek et&#160;al., 1983</xref>; <xref rid="B219" ref-type="bibr">Zhang et&#160;al., 2007</xref>).</p><p>Originally developed in the 1960s and 70s, a solubilized antigen vaccine was derived from phase I <italic toggle="yes">C. burnetii</italic> using trichloroacetic acid (TCA) extraction (<xref rid="B96" ref-type="bibr">Kaz&#225;r et&#160;al., 1982</xref>). This vaccine showed &gt;90% protective efficacy in mice and guinea pigs challenged by intraperitoneal injection with phase I <italic toggle="yes">C. burnetii</italic> and, in humans vaccinated with a two-dose regimen, positive sera was detected in 74.4% of volunteers at 5 weeks post-vaccination. The TCA vaccine also resulted in overall high rates of local reactions in humans, ranging from 27.9% to 63.9%, but a decrease in the severity of these reactions compared to the WCV (<xref rid="B96" ref-type="bibr">Kaz&#225;r et&#160;al., 1982</xref>). A live attenuated vaccine, M-44, was developed in Russia in the 1960s by serial passage of the Grita strain of <italic toggle="yes">C. burnetii</italic> forty-four times through embryonated chicken eggs. M-44 showed a marked loss of virulence when inoculated in guinea pigs and mice (<xref rid="B120" ref-type="bibr">Marmion, 1967</xref>). Although this vaccine provided significant protection against Q fever in animal and human experiments and showed reduced local and systemic reactions, concerns about the safety of attenuated <italic toggle="yes">C. burnetii</italic> vaccines prevented their general use (<xref rid="B160" ref-type="bibr">Robinson and Hasty, 1974</xref>). Indeed, one study reported that the M-44 vaccine could not only persist in tested animals for long periods, but also induce inflammation in the liver, spleen, and heart of vaccinated guinea pigs (<xref rid="B93" ref-type="bibr">Johnson et&#160;al., 1977</xref>).</p><p>Perhaps the most well-developed novel vaccine strategy to date is the chloroform:methanol residue (CMR) vaccine developed in the 1980s by the Rocky Mountain Laboratories in the United States. This method separated whole cell material into a soluble fraction, mainly composed of lipids, and a precipitate or residual fraction, composed of LPS, proteins, and peptidoglycans, which was developed as the CMR vaccine (<xref rid="B207" ref-type="bibr">Williams and Cantrell, 1982</xref>; <xref rid="B208" ref-type="bibr">Williams et&#160;al., 1992</xref>). A prime-boost regimen of the CMR vaccine provided similar protection compared to WCV in guinea pigs administered 1.4x10<sup>10</sup> phase I <italic toggle="yes">C. burnetii</italic> by intraperitoneal injection (<xref rid="B208" ref-type="bibr">Williams et&#160;al., 1992</xref>). More recently, a phase I clinical trial of the CMR vaccine produced significant anti-<italic toggle="yes">C. burnetii</italic> IgG titers and effective T cell priming. Though 75% and 65% of the 20 participants developed local reactions after the prime and boost vaccinations, respectively, these local reactions appeared less persistent than those reported with the WCV, peaking at approximately 2 to 3 days post-vaccination and resolving by 7 days post (<xref rid="B200" ref-type="bibr">Waag et&#160;al., 2008</xref>). However, further clinical safety and efficacy trials of this vaccine have not been performed.</p></sec><sec id="s15"><title>Current research for novel <italic toggle="yes">C. burnetii</italic> vaccines</title><p>Since the turn of the millennium, two more events prompted renewed interest in the development of non-reactogenic vaccines against <italic toggle="yes">C. burnetii</italic>. Between 2007 and 2010, a large outbreak of more than 4,000 cases of Q fever occurred in humans in the Netherlands linked to infections among several dairy goat farms. An emergency vaccination program using Q-VAX<sup>&#174;</sup> was implemented to help control the outbreak but was hindered by the need for pre-vaccination screening. 22% of high-risk individuals were excluded from the vaccination program due to positive skin test or serology (<xref rid="B88" ref-type="bibr">Isken et&#160;al., 2013</xref>). Additionally, U.S. military deployment to rural areas in developing countries in the early 2000s has led to increased exposure risk in military personnel as evidenced by sporadic infections and seroconversion rates of 2.1-7.2% (<xref rid="B72" ref-type="bibr">Gleeson et&#160;al., 2007</xref>; <xref rid="B163" ref-type="bibr">Royal et&#160;al., 2013</xref>). These exposure risks as well as <italic toggle="yes">C. burnetii</italic>&#8217;s status as a potential bioweapon substantiate the need for a safe and effective vaccine for military troops and other at-risk populations.</p><p>In some recent studies, novel adjuvants have facilitated the development of new subunit and solubilized antigen vaccines for <italic toggle="yes">C. burnetii.</italic> The increased availability of the number and types of vaccine adjuvants have not only allowed researchers to overcome the decreased protective efficacy of subunit vaccines but also refine immune responses. A <italic toggle="yes">C. burnetii</italic> subunit vaccine using different combinations of TLR agonist adjuvants was effective in protecting mice and guinea pigs against aerosol challenge. While some adjuvant combinations still incited vaccine site granulomas, one adjuvant combination demonstrated a significant reduction in local adverse responses (<xref rid="B71" ref-type="bibr">Gilkes et&#160;al., 2020</xref>; <xref rid="B68" ref-type="bibr">Fratzke et&#160;al., 2021b</xref>). In a separate study, a solubilized protein vaccine derived from phase II <italic toggle="yes">C. burnetii</italic> combined with the TLR9 agonist adjuvant CpG, which stimulates strong T cell memory responses, showed significant protection against aerosol challenge in mice, guinea pigs, and non-human primates and marked reduction in hypersensitivity responses in sensitized guinea pigs (<xref rid="B78" ref-type="bibr">Gregory et&#160;al., 2021</xref>). This strategy is appealing because it does not rely on cultivation of <italic toggle="yes">C. burnetii</italic> in a high-containment BL3 laboratory.</p><p>Advances in genetics and molecular biology have also allowed for the creation of new mutant strains of <italic toggle="yes">C. burnetii</italic> which do not express potentially reactogenic antigens. A mutant strain of phase I <italic toggle="yes">C. burnetii</italic> lacking the type IV secretion system, <italic toggle="yes">C. burnetii dot/icm</italic>, was recently tested as an alternative WCV (<xref rid="B113" ref-type="bibr">Long et&#160;al., 2021</xref>). This mutant WCV provided similar protection to the wild-type WCV in a guinea pig challenge experiment. Although evaluation in sensitized guinea pigs showed mild reductions in local erythema and induration, histologic evaluation of vaccination sites did not reveal a significant reduction in the severity of local inflammation compared to the wild-type WCV (<xref rid="B113" ref-type="bibr">Long et&#160;al., 2021</xref>). This strategy was refined by creating a <italic toggle="yes">dot/icm</italic> Dugway mutant, a <italic toggle="yes">C. burnetii</italic> isolate that is not virulent in animal models including mice and guinea pigs in its wild-type form (<xref rid="B165" ref-type="bibr">Russell-Lodrigue et&#160;al., 2009</xref>; <xref rid="B185" ref-type="bibr">Tesfamariam et&#160;al., 2022</xref>). Vaccination with <italic toggle="yes">dot/icm</italic> Dugway provides similar protection to WCV and reduced the reactogenicity (<xref rid="B185" ref-type="bibr">Tesfamariam et&#160;al., 2022</xref>). These recent attempts to produce safer, novel vaccines have yet to be tested in human clinical trials. Although these formulations are ready for phased trials, we hope that novel strategies to identify B and T cells antigens developed during the Sars-Cov-2 pandemic are used to further identify potentially protective epitopes for testing in novel delivery platforms.</p></sec><sec id="s16"><title>Anaplasmataceae</title><sec id="s16_1"><title>Bacteria and disease overview</title><p>The incidence of tick-borne diseases in the United States has increased over the past two decades. This includes more prevalence of acute febrile tick-borne diseases in humans caused by many species of the genera <italic toggle="yes">Ehrlichia</italic> and <italic toggle="yes">Anaplasma</italic> which are mainly transmitted by Lone Star ticks and Blacklegged ticks respectively (<xref rid="B158" ref-type="bibr">Rikihisa, 2010</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). This increased burden and the associated morbidity highlights the need for safe and efficacious vaccines. The most common causes of human infections are <italic toggle="yes">Ehrlichia chaffeensis</italic> which causes human monocytic ehrlichiosis (HME) and <italic toggle="yes">Anaplasma phagocytophilum</italic> which causes human granulocytic anaplasmosis (HGA) (<xref rid="B89" ref-type="bibr">Ismail and Mcbride, 2017</xref>). Although there are other species in each genus that can cause infections in humans, we will focus on <italic toggle="yes">E. chaffeensis</italic> and <italic toggle="yes">A. phagocytophilum</italic>. Both cause flu-like illnesses that often go misdiagnosed, thus, the actual incidence of the disease is much higher. The therapy of choice is the broad-spectrum antibiotic doxycycline, which is only effective if initiated early on (<xref rid="B83" ref-type="bibr">Hamburg et&#160;al., 2008</xref>). Vaccination therefore would be the most effective intervention to prevent the spread of these emerging infectious diseases. The major challenges to developing efficacious vaccines for <italic toggle="yes">E. chaffeensis</italic> and <italic toggle="yes">A. phagocytophilum</italic> include antigen variability and these bacteria (like most obligate intracellular pathogens) subvert the innate and adaptive immune responses which makes vaccine development even more challenging (<xref rid="B169" ref-type="bibr">Salje, 2021</xref>). Finally, the major challenge for all obligate intracellular pathogens remains the lack of genetic tools for manipulation (<xref rid="B127" ref-type="bibr">Mcclure et&#160;al., 2017</xref>). This lack of genetic tools has hampered the identification of pathogenic mechanisms, which is important to designing effective vaccines. Again, we hope that novel strategies to identify B and T cells antigens developed during the Sars-Cov-2 pandemic are used to further identify potentially protective epitopes.</p></sec><sec id="s16_2"><title>CoPs</title><p>Rational vaccine development can resolve some of these issues by deciphering the immune correlates of protection from infection-resolved cases. Strong immunity can be developed in both humans and animals that have recovered from Ehrlichiosis and Anaplasmosis. Understanding what drives immunity during natural infection in animal models has provided many clues for vaccine strategies for both HME and HGA. A Th1-mediated cellular response seems to be important for the clearance of infection. The first clue that IFN-&#947; was important for clearance of infection came from <italic toggle="yes">in vitro</italic> studies with human monocytes demonstrating that pre-treatment with IFN-&#947; inhibited infection with <italic toggle="yes">E. chaffeensis</italic> (<xref rid="B13" ref-type="bibr">Barnewall and Rikihisa, 1994</xref>). Shortly thereafter several mouse models of infection were developed including <italic toggle="yes">Ixodes ovatus</italic> ehrlichia (IOE) which demonstrated that IFN-&#947; production by CD4 T cells was essential for resolving infection (<xref rid="B20" ref-type="bibr">Bitsaktsis et&#160;al., 2004</xref>). Studies in IFN-&#947; -/- mice demonstrated that Th1 skewed response with IFN-&#947; production also facilitated bacterial clearance of <italic toggle="yes">A. phagocytophilum</italic> where it is involved in early infection control but dispensable at later timepoints (<xref rid="B4" ref-type="bibr">Akkoyunlu and Fikrig, 2000</xref>). However, it was later determined that although CD4+ T cells are required for pathogen clearance Th1 cytokines are dispensible and therefore the mechanism of protection remains to be identified (<xref rid="B19" ref-type="bibr">Birkner et&#160;al., 2008</xref>). This highlights the paradigm that Th1 CD4 T cells are required to resolve infections with most intracellular bacterial pathogens, however, they do not explain all of the protective mechanisms which occur through unknown mechanisms (<xref rid="B186" ref-type="bibr">Thakur et&#160;al., 2019</xref>).</p><p>The importance of these cellular responses goes against to dogma that most vaccines historically have aimed to induce neutralizing antibodies. This strategy is not as effective for intracellular pathogens, where antibodies can induce uptake and infection of cells by a mechanism termed antibody-dependent enhancement (ADE) which can exacerbate natural infection (<xref rid="B188" ref-type="bibr">Thomas et&#160;al., 2006</xref>). Although this is possible, high antibody titers are seen after the resolution of natural infection with both <italic toggle="yes">E. chaffeensis</italic> and <italic toggle="yes">A. phagocytophilum</italic> in humans (<xref rid="B114" ref-type="bibr">Lotric-Furlan et&#160;al., 2001</xref>; <xref rid="B3" ref-type="bibr">Aguero-Rosenfeld et&#160;al., 2002</xref>). Other clues to the protective nature of sera have been demonstrated in animal models of infection. For example, although wild-type inbred mice are relatively resistant to <italic toggle="yes">E. chaffeensis</italic> infection, SCID mice provide a relevant animal model of infection. Passive transfer of sera from <italic toggle="yes">E. chaffeensis</italic> infection resolved wild-type mice to SCID mice before or after inoculation with <italic toggle="yes">E. chaffeensis</italic> provides a measurable level of protection (<xref rid="B209" ref-type="bibr">Winslow et&#160;al., 2000</xref>). However, this study also confirmed that T cells are required for complete clearance of infection highlighting again the importance of cellular response in protection (<xref rid="B209" ref-type="bibr">Winslow et&#160;al., 2000</xref>). The mechanism of antibody-mediated protection for <italic toggle="yes">E. chaffeensis</italic> was further elucidated to depend on complement and Fc&#947;R-mediated phagocytosis (<xref rid="B213" ref-type="bibr">Yager et&#160;al., 2005</xref>). Individuals infected with <italic toggle="yes">A. phagocytophilum</italic> have an early IgG antibody response to 2 proteins at 40 and 44-kDa respectively suggesting an important role for CD4 T cell help (<xref rid="B94" ref-type="bibr">Jw et&#160;al., 1997</xref>). This class switching in humans plus the evidence that CD4 T cells are important for clearance of infection, demonstrates that both humoral and cell-mediated immunity are involved. Studies in mice have also demonstrated that humoral response to <italic toggle="yes">A. phagocytophilum</italic> provides partial protection (<xref rid="B184" ref-type="bibr">Sun et&#160;al., 1997</xref>). Antibody responses must be against surface-exposed proteins to elicit neutralizing effects. However, it is more convoluted with intracellular bacteria where it is common that serum transferred to athymic mice is not protective indicating that neutralization alone may not confer protection (<xref rid="B87" ref-type="bibr">Humphres and Hinrichs, 1981</xref>; <xref rid="B156" ref-type="bibr">Rhinehart-Jones et&#160;al., 1994</xref>). All this information from animal models and human infections demonstrates that both humoral and cell-mediated responses will be necessary to provide protection and therefore any vaccine candidate must elicit both responses.</p></sec></sec><sec id="s17"><title>
<italic toggle="yes">Ehrlichia</italic> spp. vaccines</title><p>One of the major challenges for vaccine development for obligate intracellular bacteria was the choice of antigen. As <italic toggle="yes">Ehrlichia</italic> spp. lack lipopolysaccharides; glycoconjugate strategies are not valid making identification of protein antigens necessary. Until very recently the number of immunoreactive proteins identified was only a handful including several tandem repeat proteins (TRPs) like gp120 (<xref rid="B118" ref-type="bibr">Luo et&#160;al., 2009</xref>), an ankyrin protein Ank200 (<xref rid="B119" ref-type="bibr">Luo et&#160;al., 2010</xref>), and the major outer membrane protein (OMP) (<xref rid="B140" ref-type="bibr">Ohashi et&#160;al., 1998</xref>). However, advancements in next-generation sequencing in recent years have allowed the discovery of antigenic proteins using ANTIGENpro which identifies potentially protective antigens for a humoral response (<xref rid="B116" ref-type="bibr">Luo et&#160;al., 2020</xref>, <xref rid="B117" ref-type="bibr">2021</xref>). The <italic toggle="yes">E. chaffeensis</italic> antigens identified in these studies were mostly hypothetical secreted proteins that require the native protein structure to be conserved for antibody recognition, indicating that they are not linear epitopes (<xref rid="B116" ref-type="bibr">Luo et&#160;al., 2020</xref>, <xref rid="B117" ref-type="bibr">2021</xref>). The immunogenicity of these novel antigens was tested against HME human convalescent sera to show that they were recognized after infection (<xref rid="B116" ref-type="bibr">Luo et&#160;al., 2020</xref>, <xref rid="B117" ref-type="bibr">2021</xref>). Although this study identified novel antigens none of them were tested as vaccine candidates, so it remains to be determined if any or a combination of them are protective.</p><p>Another recent study used subtractive genomics and reverse vaccinology to identify surface exposed proteins with linear B cell epitopes (<xref rid="B166" ref-type="bibr">Sabzi et&#160;al., 2023</xref>). A multi-epitope vaccine was designed and used in a C-ImmSim immunoreactivity simulation to demonstrate a strong Th1 response, however, this would also have to be demonstrated in animal models (<xref rid="B166" ref-type="bibr">Sabzi et&#160;al., 2023</xref>). The influx of genome sequences for different <italic toggle="yes">E. chaffeensis</italic> strains will help in identifying antigens using subtractive genetics and reverse vaccinology to develop a safe and efficacious vaccine.</p><p>One of the other major challenges for vaccine development for <italic toggle="yes">Ehrlichia</italic> spp. is the lack of appropriate animal models. The outer membrane protein P28 (OMP-19) has a long history of protection studies in different animal models of <italic toggle="yes">E. chaffeensis</italic>. The earliest study demonstrated that intraperitoneal immunization of P28 could prevent blood-borne infection of <italic toggle="yes">E. chaffeensis</italic> in BALB/c mice, which was a feat that the time but is not a physiologically relevant animal model. After this initial study, passive transfer studies showed that monoclonal antibodies to P28 OMP could prevent disease caused by <italic toggle="yes">E. chaffeensis</italic> in SCID mice (<xref rid="B176" ref-type="bibr">Shu-Yi Li et&#160;al., 2001</xref>). This study had to be done in SCID mice since <italic toggle="yes">E. chaffeensis</italic> does not infect wild-type mice in a physiologically relevant manner. Therefore, many of the other vaccine studies used <italic toggle="yes">E. muris</italic> as a surrogate in mice, for mild virulence in humans, or IOE in mice, for fatal infection in humans, to test the protective ability of P28 (<xref rid="B134" ref-type="bibr">Nandi et&#160;al., 2007</xref>; <xref rid="B42" ref-type="bibr">Crocquet-Valdes et&#160;al., 2011</xref>).</p><p>The study with IOE established that P28-19 could provide partial protection as not all immunized mice survived with high humoral and cell-mediated responses indicating a Th1 skew (<xref rid="B134" ref-type="bibr">Nandi et&#160;al., 2007</xref>). Vaccination and challenge with P28 and <italic toggle="yes">E. muris</italic> demonstrated IFN-&#947; specific CD4+ T cells and increased IgG2c after vaccination and challenge indicating a Th1 skewed response and again provided partial protection (<xref rid="B42" ref-type="bibr">Crocquet-Valdes et&#160;al., 2011</xref>). Another study using vaccination with peptide epitopes from P28 and Hsp60 and challenge with <italic toggle="yes">E. muris</italic> demonstrated similar results which consisted of partial protection and a Th1 skew (<xref rid="B189" ref-type="bibr">Thomas et&#160;al., 2011</xref>).</p><p>Additionally, a TRP protein P29 from <italic toggle="yes">E. muris</italic> has been used in vaccination challenge experiments to show a reduction in bacteria in the liver and spleen but not the lung and blood in a high dose challenge (<xref rid="B187" ref-type="bibr">Thirumalapura et&#160;al., 2013</xref>). All these studies demonstrate that there are immunogenic proteins that induce a Th1 skewed response but none of these provide protection alone.</p><p>The development of transposon mutagenesis in <italic toggle="yes">E. chaffeensis</italic> in 2013 led to the testing of several attenuated mutants as vaccine candidates (<xref rid="B35" ref-type="bibr">Cheng et&#160;al., 2013</xref>). Two mutants with <italic toggle="yes">in vivo</italic> growth defects were tested as live attenuated vaccine candidates in dogs (incidental host) and deer (reservoir host) with promising results (<xref rid="B133" ref-type="bibr">Nair et&#160;al., 2015</xref>). These results were extended by demonstrating that vaccination with Ech_0660 transposon mutant provided significant protection followed by challenge in dogs after tick-transmission of <italic toggle="yes">E. chaffeensis</italic> and induced both humoral, Th1, and Th17 responses (<xref rid="B129" ref-type="bibr">Mcgill et&#160;al., 2016</xref>). After this first report of protection, vaccination with entry trigger protein Etp-E also demonstrated accelerated clearance from dogs as was observed using the attenuated live vaccine (<xref rid="B24" ref-type="bibr">Budachetri et&#160;al., 2020</xref>). This study was followed up with another study using the same tick-transmission model and two other subunit vaccines OMP-1B and VirB2-4 which caused clearance of <italic toggle="yes">E. chaffeensis</italic> at an earlier time-point after tick transmission (<xref rid="B23" ref-type="bibr">Budachetri et&#160;al., 2022</xref>).</p><p>All these studies demonstrate that there are very good immunogenic proteins in <italic toggle="yes">E. chaffeensis</italic> and the right combination of them with a Th1 skewing adjuvant could provide protection. Also, very interestingly, the induction of Th17 responses with the live attenuated vaccine is important as these responses are important in the clearance of other intracellular bacteria.</p></sec><sec id="s18"><title>
<italic toggle="yes">Anaplasma</italic> spp. vaccines</title><p>As with <italic toggle="yes">E. chaffeensis</italic>, the major barrier to the development of a vaccine against <italic toggle="yes">A. phagocytophilum</italic> is antigen choice. Although a lot of research has been done to develop a vaccine against <italic toggle="yes">A. marginale</italic> in cattle, very little progress has been made to accomplish this goal against <italic toggle="yes">A. phagocytophilum</italic> for humans. Once again, <italic toggle="yes">A. phagocytophilum</italic> lacks LPS, and therefore glycoconjugate vaccine strategies are irrelevant. MSP2(P44) is an immunodominant OMP of <italic toggle="yes">A. phagocytophilum</italic> which was determined using human convalescent serum. However, only the N and C termini are conserved (<xref rid="B94" ref-type="bibr">Jw et&#160;al., 1997</xref>). The central hypervariable region (HVR) is varied using pseudogenes and a gene combinatorial conversion mechanism (<xref rid="B10" ref-type="bibr">Barbet et&#160;al., 2003</xref>). Therefore, although antibody responses to MSP2(P44) show some level of protection, the extreme variation of this protein makes it a poor candidate for a universal vaccine (<xref rid="B104" ref-type="bibr">Kim and Rikihisa, 1998</xref>).</p><p>On the other hand, <italic toggle="yes">A. phagocytophilum</italic> encodes 3 surface-exposed adhesins, which could serve as targets for an antibody-mediated vaccine to prevent cell invasion. Antibodies targeting domains that prevent binding of OmpA, Asp14, or AipA reduced infection in host cells <italic toggle="yes">in vitro</italic> by 50%, whereas, using a combination of all 3 reduced infection by 80% (<xref rid="B171" ref-type="bibr">Seidman et&#160;al., 2015</xref>). This laid the groundwork to determine the relevance of these 3 adhesins to infection <italic toggle="yes">in vivo</italic> by immunizing mice with keyhole limpet conjugated peptides from the binding domains of each (<xref rid="B132" ref-type="bibr">Naimi Waheeda et&#160;al., 2020</xref>). Interestingly, only antibodies to the binding domains of Asp14 and AipA inhibited <italic toggle="yes">in vitro</italic> infection after vaccination (<xref rid="B132" ref-type="bibr">Naimi Waheeda et&#160;al., 2020</xref>). This vaccine strategy also induced antigen-specific IFN&#947;-producing CD8+ T cells but not CD4+ T cells (<xref rid="B132" ref-type="bibr">Naimi Waheeda et&#160;al., 2020</xref>). IFN&#947; is important for the control of <italic toggle="yes">A. phagocytophilum</italic> presumably by activating macrophages. Although it was only partially protective, the addition of other T cell antigens or the use of a different adjuvant like CpG to induce a better Th1 response could elicit better protection.</p><p>Another strategy for an <italic toggle="yes">A. phagocytophilum</italic> vaccine is to use subdominant protein antigens from the type IV secretion system VirB9 and VirB10 a strategy that has been more widely investigated for <italic toggle="yes">A. marginales</italic> (<xref rid="B43" ref-type="bibr">Crosby et&#160;al., 2018</xref>). The protection by VirB10 was marginal at best but did produce antigen-specific IFN&#947;+ CD4+ T cells suggesting that a vaccine strategy that includes VirB10 with other antigens in combination with an appropriate adjuvant may provide a better level of protection (<xref rid="B43" ref-type="bibr">Crosby et&#160;al., 2018</xref>).</p></sec><sec id="s19"><title>Tick vaccines</title><p>A strategy that has emerged for the treatment of tick-borne diseases is to vaccinate against the tick instead of the pathogen carried by the tick. The acquired resistance or so-called &#8220;tick immunity&#8221; after repeated tick bites was first described by Trager in 1939 and is associated with inflammation at the site of tick bite (<xref rid="B191" ref-type="bibr">Trager, 1939</xref>). This type of resistance usually develops in non-natural hosts (<xref rid="B135" ref-type="bibr">Narasimhan et&#160;al., 2021</xref>). Understanding how this resistance develops has helped the development of tick-specific vaccines. In the most general terms, anti-tick vaccines target both concealed and non-concealed protein antigens which are exposed after the tick starts a blood meal. Strategies include targeting tick attachment, feeding, and salivary gland proteins (<xref rid="B47" ref-type="bibr">De La Fuente et&#160;al., 2020</xref>). The BM86-based vaccine for control of cattle tick infestations is the only licensed tick vaccine marketed as Gavac&#8482; in Cuba and TickGUARD<sup>PLUSTM</sup> in Australia (<xref rid="B206" ref-type="bibr">Willadsen et&#160;al., 1989</xref>). As resistance has grown to chemical acaricides, this strategy has become the lead candidate to combat ticks and disease transmission in livestock. The development of anti-tick vaccines has also benefited from machine learning and reverse vaccinology. An <italic toggle="yes">A. phagocytophlium</italic> specific vaccinomic approach used previously published transcriptomic and proteomic data on <italic toggle="yes">A. phagocytophilum</italic> infected <italic toggle="yes">I. scapularis</italic> to identify candidate protective antigens and determine their homologs in the closely related <italic toggle="yes">I. ricinus</italic> (<xref rid="B40" ref-type="bibr">Contreras et&#160;al., 2017</xref>). This strategy identified 2 potential tick-protective antigens that are involved in pathogen infection and transmission.</p><p>More recently, a cocktail of 19 salivary proteins based on a previous analysis of the <italic toggle="yes">Ixodes scapularis</italic> sialome was used to create a nucleoside-modified mRNA-encapsulated lipid nanoparticle for vaccinated guinea pigs (<xref rid="B167" ref-type="bibr">Sajid et&#160;al., 2021</xref>). None of the vaccinated guinea pigs were positive for <italic toggle="yes">Borrelia burgdorferi</italic> while 46% of the unvaccinated guinea pigs were culture-positive for <italic toggle="yes">B. burgdorferi</italic> (<xref rid="B167" ref-type="bibr">Sajid et&#160;al., 2021</xref>). Erythema at the site of tick attachment was a hallmark of tick-resistance (<xref rid="B167" ref-type="bibr">Sajid et&#160;al., 2021</xref>). This strategy should also work for <italic toggle="yes">A. phagocytophilum</italic> which is transmitted by <italic toggle="yes">I. scapularis</italic> and other ixodid ticks. The most attractive part of anti-tick vaccines is that they should prevent any transmission of infectious agents carried by the said tick.</p></sec><sec sec-type="discussion" id="s20"><title>Discussion</title><p>This review provides a broad overview of what is known about the immune responses to Rickettsiaceae, <italic toggle="yes">Coxiella burnetti</italic>, and <italic toggle="yes">Anaplasmataceae</italic> and the challenges that have been faced in developing safe and efficacious vaccines to date. The identification and testing of a handful of antigens for each of the obligate intracellular bacteria has taken at least half a century. It is our view that any vaccination strategy that stimulates a Th1 mediated response with the production of pathogen specific antibodies, CD4+ T cell, and CD8+ cytotoxic T cell will be most effective for any of the obligate intracellular bacteria as discussed throughout this review. The next phases of novel vaccine development for this group of obligate intracellular pathogens will use the new vaccinology approaches described in this review based on genomics and proteomics, with the inclusion of machine learning algorithms to define protective antigens. Once these antigens or epitopes are identified we believe their delivery using the licensed mRNA and viral vectors DNA used during the SARS-CoV-2 pandemic should provide optimal protection because they induce the optimal protection described above providing both CD4+ T and CD8+ T cells responses in addition humoral responses. Additionally, these delivery methods do not rely on producing subunit antigens which has hampered the development of these vaccines as they are often difficult to produce. These innovations should allow for the development and testing of safe and effective vaccines soon for <italic toggle="yes">Rickettsiaceae</italic>, <italic toggle="yes">C. burnetti</italic>, and <italic toggle="yes">Anaplasmataceae</italic>. The challenges that remain will be the development of CoPs that can be used to define protection by CD4+ and CD8+ T cells in the clinical phases of testing. Although defining CoPs remains a challenge the other innovations discussed in this review should greatly excelerate the identification and testing of novel antigens. The need for these vaccines will continue as the rise of infections and expansion of vector territories for these obligate intracellular bacteria continues.</p></sec><sec sec-type="author-contributions" id="s21"><title>Author contributions</title><p>EV: Conceptualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. AF: Writing &#8211; original draft, Writing &#8211; review &amp; editing. AG: Writing &#8211; original draft, Writing &#8211; review &amp; editing. JD: Writing &#8211; original draft, Writing &#8211; review &amp; editing. JS: Funding acquisition, Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p></sec></body><back><sec sec-type="COI-statement" id="s23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s24"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abinanti</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name></person-group> (<year>1957</year>). <article-title>Protective or neutralizing antibody in Q fever</article-title>. <source>Am. J. Hyg</source><volume>66</volume> (<issue>2</issue>), <page-range>173&#8211;195</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a119894</pub-id><pub-id pub-id-type="pmid">13458182</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adem</surname><given-names>P. V.</given-names></name></person-group> (<year>2019</year>). <article-title>Emerging and re-emerging rickettsial infections</article-title>. <source>Semin. Diagn. Pathol.</source><volume>36</volume> (<issue>3</issue>), <fpage>146</fpage>&#8211;<lpage>151</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1053/j.semdp.2019.04.005</pub-id><pub-id pub-id-type="pmid">31101391</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguero-Rosenfeld</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Donnarumma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zentmaier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noto</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York</article-title>. <source>J. Clin. Microbiol.</source><volume>40</volume>, <fpage>2612</fpage>&#8211;<lpage>2615</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/JCM.40.7.2612-2615.2002</pub-id><pub-id pub-id-type="pmid">12089287</pub-id><pub-id pub-id-type="pmcid">PMC120546</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akkoyunlu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fikrig</surname><given-names>E.</given-names></name></person-group> (<year>2000</year>). <article-title>Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia</article-title>. <source>Infection Immun.</source><volume>68</volume>, <fpage>1827</fpage>&#8211;<lpage>1833</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.68.4.1827-1833.2000</pub-id><pub-id pub-id-type="pmcid">PMC97354</pub-id><pub-id pub-id-type="pmid">10722570</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anacker</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>List</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L. A.</given-names></name></person-group> (<year>1985</year>). <article-title>Characterization of monoclonal antibodies protecting mice against Rickettsia rickettsii</article-title>. <source>J. Infect. Dis.</source><volume>151</volume>, <fpage>1052</fpage>&#8211;<lpage>1060</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/151.6.1052</pub-id><pub-id pub-id-type="pmid">3923129</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Shive</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2007</year>). <article-title>T cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and B cells are crucial for disease development in coxiella burnetii infection in mice</article-title>. <source>Infection Immun.</source><volume>75</volume>, <fpage>3245</fpage>&#8211;<lpage>3255</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.01767-06</pub-id><pub-id pub-id-type="pmcid">PMC1932934</pub-id><pub-id pub-id-type="pmid">17438029</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appay</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zaunders</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Papagno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jaramillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Characterization of CD4(+) CTLs ex vivo</article-title>. <source>J. Immunol.</source><volume>168</volume>, <fpage>5954</fpage>&#8211;<lpage>5958</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.168.11.5954</pub-id><pub-id pub-id-type="pmid">12023402</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascher</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Oster</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Harber</surname><given-names>P. I.</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>C. E.</given-names></name></person-group> (<year>1978</year>). <article-title>Initial clinical evaluation of a new rocky mountain spotted fever vaccine of tissue culture origin</article-title>. <source>J. Infect. Dis.</source><volume>138</volume>, <fpage>217</fpage>&#8211;<lpage>221</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/138.2.217</pub-id><pub-id pub-id-type="pmid">355580</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Diercks</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Proffitt</surname><given-names>J. E.</given-names></name></person-group> (<year>1948</year>). <article-title>Preparation of a serological antigen and a vaccine for experimental tsutsugamushi disease (Scrub typhus)*,&#8224;</article-title>. <source>J. Immunol.</source><volume>60</volume>, <fpage>431</fpage>&#8211;<lpage>441</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.60.3.431</pub-id><pub-id pub-id-type="pmid">18890201</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbet</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Meeus</surname><given-names>P. F. M.</given-names></name><name name-style="western"><surname>B&#233;langer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bowie</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Expression of multiple outer membrane protein sequence variants from a single genomic locus of anaplasma phagocytophilum</article-title>. <source>Infection Immun.</source><volume>71</volume>, <fpage>1706</fpage>&#8211;<lpage>1718</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.71.4.1706-1718.2003</pub-id><pub-id pub-id-type="pmcid">PMC152091</pub-id><pub-id pub-id-type="pmid">12654783</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbier</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wooster</surname><given-names>R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D. G.</given-names></name></person-group> (<year>2022</year>). <article-title>The clinical progress of mRNA vaccines and immunotherapies</article-title>. <source>Nat. Biotechnol.</source><volume>40</volume>, <fpage>840</fpage>&#8211;<lpage>854</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41587-022-01294-2</pub-id><pub-id pub-id-type="pmid">35534554</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wehrly</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence</article-title>. <source>Mol. Microbiol.</source><volume>74</volume>, <fpage>1459</fpage>&#8211;<lpage>1470</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2958.2009.06947.x</pub-id><pub-id pub-id-type="pmid">20054881</pub-id><pub-id pub-id-type="pmcid">PMC2814410</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnewall</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group> (<year>1994</year>). <article-title>Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin</article-title>. <source>Infection Immun.</source><volume>62</volume>, <fpage>4804</fpage>&#8211;<lpage>4810</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.62.11.4804-4810.1994</pub-id><pub-id pub-id-type="pmcid">PMC303190</pub-id><pub-id pub-id-type="pmid">7927758</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beare</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pablo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>D. C.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Candidate antigens for Q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii protein microarray</article-title>. <source>Clin. Vaccine Immunol.</source><volume>15</volume>, <fpage>1771</fpage>&#8211;<lpage>1779</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00300-08</pub-id><pub-id pub-id-type="pmid">18845831</pub-id><pub-id pub-id-type="pmcid">PMC2593175</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beare</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Heinzen</surname><given-names>R. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation</article-title>. <source>PloS Pathog.</source><volume>14</volume>, <elocation-id>e1006922</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1006922</pub-id><pub-id pub-id-type="pmid">29481553</pub-id><pub-id pub-id-type="pmcid">PMC5843353</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Lackman</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Meis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hadlow</surname><given-names>W. J.</given-names></name></person-group> (<year>1964</year>). <article-title>Recurrent reaction of site of q fever vaccination in a sensitized person</article-title>. <source>Mil Med.</source><volume>129</volume>, <fpage>591</fpage>&#8211;<lpage>595</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/milmed/129.7.591</pub-id><pub-id pub-id-type="pmid">14199980</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berge</surname><given-names>T. O.</given-names></name><name name-style="western"><surname>Gauld</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Kitaoka</surname><given-names>M.</given-names></name></person-group> (<year>1949</year>). <article-title>A Field Trial of a Vaccine prepared from the Volner Strain of Rickettsia tsutsugamushi</article-title>. <source>Am. J. Hygiene</source><volume>50</volume>, <fpage>337</fpage>&#8211;<lpage>342</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a119366</pub-id><pub-id pub-id-type="pmid">15391985</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biberstein</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Crenshaw</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Behymer</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Franti</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Bushnell</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Riemann</surname><given-names>H. P.</given-names></name></person-group> (<year>1974</year>). <article-title>Dermal reactions and antibody responses in dairy cows and laboratory animals vaccinated with Coxiella burnetii</article-title>. <source>Cornell Vet.</source><volume>64</volume>, <fpage>387</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">4845729</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rinkler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aichele</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>The elimination of Anaplasma phagocytophilum requires CD4+ T cells, but is independent of Th1 cytokines and a wide spectrum of effector mechanisms</article-title>. <source>Eur. J. Immunol.</source><volume>38</volume>, <fpage>3395</fpage>&#8211;<lpage>3410</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.200838615</pub-id><pub-id pub-id-type="pmid">19039769</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitsaktsis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huntington</surname><given-names>J.</given-names></name><name name-style="western"><surname>Winslow</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Production of IFN-gamma by CD4 T cells is essential for resolving ehrlichia infection</article-title>. <source>J. Immunol.</source><volume>172</volume>, <fpage>6894</fpage>&#8211;<lpage>6901</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.172.11.6894</pub-id><pub-id pub-id-type="pmid">15153508</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortnick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allman</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens</article-title>. <source>J. Immunol.</source><volume>190</volume>, <fpage>5913</fpage>&#8211;<lpage>5918</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1300161</pub-id><pub-id pub-id-type="pmid">23749966</pub-id><pub-id pub-id-type="pmcid">PMC4234153</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Mogg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial</article-title>. <source>Lancet</source><volume>372</volume>, <fpage>1881</fpage>&#8211;<lpage>1893</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(08)61591-3</pub-id><pub-id pub-id-type="pmid">19012954</pub-id><pub-id pub-id-type="pmcid">PMC2721012</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budachetri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Efficacy and immune correlates of OMP-1B and virB2-4 vaccines for protection of dogs from tick transmission of ehrlichia chaffeensis</article-title>. <source>mBio</source><volume>13</volume>, <elocation-id>e0214022</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1128/mbio.02140-22</pub-id><pub-id pub-id-type="pmid">36342170</pub-id><pub-id pub-id-type="pmcid">PMC9765013</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budachetri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Teymournejad</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mestres-Villanueva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brock Guy</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>An entry-triggering protein of ehrlichia is a new vaccine candidate against tick-borne human monocytic ehrlichiosis</article-title>. <source>mBio</source><volume>11</volume>, <fpage>e00895</fpage>&#8211;<lpage>e00820</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/mBio.00895-20</pub-id><pub-id pub-id-type="pmid">32723916</pub-id><pub-id pub-id-type="pmcid">PMC7387794</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buijs</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Van Roeden</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Van Werkhoven</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Hoepelman</surname><given-names>A. I. M.</given-names></name><name name-style="western"><surname>Wever</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Bleeker-Rovers</surname><given-names>C. P.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>The prognostic value of serological titres for clinical outcomes during treatment and follow-up of patients with chronic Q fever</article-title>. <source>Clin. Microbiol. Infection</source><volume>27</volume>, <fpage>1273</fpage>&#8211;<lpage>1278</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmi.2021.03.016</pub-id><pub-id pub-id-type="pmid">33813120</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Engstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Langohr</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Glasner</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>D. A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Interferon receptor-deficient mice are susceptible to eschar-associated rickettsiosis</article-title>. <source>Elife</source><volume>10</volume>, <elocation-id>e67029</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.7554/eLife.67029.sa2</pub-id><pub-id pub-id-type="pmid">34423779</pub-id><pub-id pub-id-type="pmcid">PMC8428839</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buttrum</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ledbetter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cherla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>Both Major Histocompatibility Complex Class I (MHC-I) and MHC-II Molecules Are Required, while MHC-I Appears To Play a Critical Role in Host Defense against Primary Coxiella burnetii Infection</article-title>. <source>Infect. Immun.</source><volume>86</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00602-17</pub-id><pub-id pub-id-type="pmcid">PMC5865044</pub-id><pub-id pub-id-type="pmid">29311245</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caro-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cespedes</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Goez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>B.</given-names></name><name name-style="western"><surname>Valbuena</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>a). <article-title>Phenotype of the anti-Rickettsia CD8+ T cell response suggests cellular correlates of protection for the assessment of novel antigens</article-title>. <source>Vaccine</source><volume>32</volume>, <fpage>4960</fpage>&#8211;<lpage>4967</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.032</pub-id><pub-id pub-id-type="pmid">25043277</pub-id><pub-id pub-id-type="pmcid">PMC4138832</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caro-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Valbuena</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>b). <article-title>Discovery of novel cross-protective Rickettsia prowazekii T-cell antigens using a combined reverse vaccinology and in <italic toggle="yes">vivo</italic> screening approach</article-title>. <source>Vaccine</source><volume>32</volume>, <fpage>4968</fpage>&#8211;<lpage>4976</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.089</pub-id><pub-id pub-id-type="pmid">25010827</pub-id><pub-id pub-id-type="pmcid">PMC4145598</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrillo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Izquierdo-Useros</surname><given-names>N.</given-names></name><name name-style="western"><surname>&#193;vila-Nieto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pradenas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clotet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>538</volume>, <fpage>187</fpage>&#8211;<lpage>191</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.108</pub-id><pub-id pub-id-type="pmid">33187644</pub-id><pub-id pub-id-type="pmcid">PMC7648524</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>Y. G.-Y.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Adherence to and invasion of host cells by spotted fever group Rickettsia species</article-title>. <source>Front. Microbiol.</source><volume>1</volume>, <elocation-id>139</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2010.00139</pub-id><pub-id pub-id-type="pmid">21687751</pub-id><pub-id pub-id-type="pmcid">PMC3109342</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>A. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Scrub typhus vaccines: past history and recent developments</article-title>. <source>Hum. Vaccines</source><volume>3</volume>, <fpage>73</fpage>&#8211;<lpage>80</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.3.3.4009</pub-id><pub-id pub-id-type="pmid">17375000</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bahadur</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wig</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Mortality due to scrub typhus&#8211;report of five cases</article-title>. <source>Indian J. Med. Res.</source><volume>149</volume>, <fpage>790</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.4103/ijmr.IJMR_1314_18</pub-id><pub-id pub-id-type="pmid">31496533</pub-id><pub-id pub-id-type="pmcid">PMC6755786</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Travanty</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Garshong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Crossley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wasserberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Apperson</surname><given-names>C. S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Detection of orientia spp. Bacteria in field-collected free-living eutrombicula chigger mites, United States</article-title>. <source>Emerg. Infect. Dis.</source><volume>29</volume>, <fpage>1676</fpage>&#8211;<lpage>1679</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3201/eid2908.230528</pub-id><pub-id pub-id-type="pmid">37486323</pub-id><pub-id pub-id-type="pmcid">PMC10370866</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A. D. S.</given-names></name><name name-style="western"><surname>Indukuri</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Felsheim</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Targeted and Random Mutagenesis of Ehrlichia chaffeensis for the Identification of Genes Required for <italic toggle="yes">In vivo</italic> Infection</article-title>. <source>PloS Pathog.</source><volume>9</volume>, <elocation-id>e1003171</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1003171</pub-id><pub-id pub-id-type="pmid">23459099</pub-id><pub-id pub-id-type="pmcid">PMC3573109</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherry</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Nichols Heitman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bestul</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Kersh</surname><given-names>G. J.</given-names></name></person-group> (<year>2022</year>). <article-title>Acute and chronic Q fever national surveillance &#8211; United States 2008&#8211;2017</article-title>. <source>Zoonoses Public Health</source><volume>69</volume>, <fpage>73</fpage>&#8211;<lpage>82</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/zph.12896</pub-id><pub-id pub-id-type="pmid">34626097</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>B.-A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>N.-H.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.-S.</given-names></name></person-group> (<year>2010</year>). <article-title>Intracellular invasion by orientia tsutsugamushi is mediated by integrin signaling and actin cytoskeleton rearrangements</article-title>. <source>Infection Immun.</source><volume>78</volume>, <fpage>1915</fpage>&#8211;<lpage>1923</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.01316-09</pub-id><pub-id pub-id-type="pmcid">PMC2863532</pub-id><pub-id pub-id-type="pmid">20160019</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y. R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y. S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>A Recombinant 47-kDa Outer Membrane Protein Induces an Immune Response against Orientia tsutsugamushi Strain Boryong</article-title>. <source>Am. J. Trop. Med. Hyg</source><volume>97</volume>, <fpage>30</fpage>&#8211;<lpage>37</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4269/ajtmh.15-0771</pub-id><pub-id pub-id-type="pmid">28719308</pub-id><pub-id pub-id-type="pmcid">PMC5508880</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y. R.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Protective immunity of 56-kDa type-specific antigen of Orientia tsutsugamushi causing scrub typhus</article-title>. <source>J. Microbiol. Biotechnol.</source><volume>24</volume>, <fpage>1728</fpage>&#8211;<lpage>1735</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4014/jmb.1407.07048</pub-id><pub-id pub-id-type="pmid">25112312</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contreras</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alberdi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fern&#225;ndez de Mera</surname><given-names>I. G.</given-names></name><name name-style="western"><surname>Krull</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nijhof</surname><given-names>A.</given-names></name><name name-style="western"><surname>Villar</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Vaccinomics approach to the identification of candidate protective antigens for the control of tick vector infestations and anaplasma phagocytophilum infection</article-title>. <source>Front. Cell. Infection Microbiol.</source><volume>7</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00360</pub-id><pub-id pub-id-type="pmcid">PMC5552662</pub-id><pub-id pub-id-type="pmid">28848718</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocquet-Valdes</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>D&#237;az-Montero</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>A. D. T.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis</article-title>. <source>Vaccine</source><volume>20</volume>, <fpage>979</fpage>&#8211;<lpage>988</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(01)00377-2</pub-id><pub-id pub-id-type="pmid">11738766</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocquet-Valdes</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Thirumalapura</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>H. L.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Immunization with Ehrlichia P28 outer membrane proteins confers protection in a mouse model of ehrlichiosis</article-title>. <source>Clin. Vaccine Immunol. CVI</source><volume>18</volume>, <fpage>2018</fpage>&#8211;<lpage>2025</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.05292-11</pub-id><pub-id pub-id-type="pmid">22030371</pub-id><pub-id pub-id-type="pmcid">PMC3232687</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosby</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Barbet</surname><given-names>A. F.</given-names></name></person-group> (<year>2018</year>). <article-title>VirB10 vaccination for protection against Anaplasma phagocytophilum</article-title>. <source>BMC Microbiol.</source><volume>18</volume>, <fpage>217</fpage>&#8211;<lpage>217</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12866-018-1346-x</pub-id><pub-id pub-id-type="pmid">30563470</pub-id><pub-id pub-id-type="pmcid">PMC6299599</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dasch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bourgeois</surname><given-names>A.</given-names></name></person-group> (<year>1981</year>). &#8220;<article-title>Antigens of the typhus group of rickettsiae: importance of the species-specific surface protein antigens in eliciting immunity</article-title>,&#8221; in <source>Rickettsiae and rickettsial diseases</source> (<publisher-name>Academic Press, Inc.</publisher-name>, <publisher-loc>New York, NY</publisher-loc>), <fpage>61</fpage>&#8211;<lpage>69</lpage>.</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dasch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rollwagen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Misiti</surname><given-names>J.</given-names></name></person-group> (<year>1984</year>). &#8220;<article-title>Approaches to subunit vaccines against the typhus rickettsiae, Rickettsia typhi and Rickettsia prowazekii</article-title>,&#8221; in <source>Microbiology-1984</source> (<publisher-name>American Society for Microbiology</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>), <fpage>251</fpage>&#8211;<lpage>256</lpage>.</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Cremoux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rousset</surname><given-names>E.</given-names></name><name name-style="western"><surname>Touratier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Audusseau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nicollet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ribaud</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Assessment of vaccination by a phase I Coxiella burnetii-inactivated vaccine in goat herds in clinical Q fever situation</article-title>. <source>FEMS Immunol. Med. Microbiol.</source><volume>64</volume>, <fpage>104</fpage>&#8211;<lpage>106</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00892.x</pub-id><pub-id pub-id-type="pmid">22066485</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Fuente</surname><given-names>J.</given-names></name><name name-style="western"><surname>Estrada-Pe&#241;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Modeling tick vaccines: A key tool to improve protection efficacy</article-title>. <source>Expert Rev. Vaccines</source><volume>19</volume>, <fpage>217</fpage>&#8211;<lpage>225</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2020.1745635</pub-id><pub-id pub-id-type="pmid">32192377</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Correlates of adjuvanticity: A review on adjuvants in licensed vaccines</article-title>. <source>Semin. Immunol.</source><volume>39</volume>, <fpage>14</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dellacasagrande</surname><given-names>J.</given-names></name><name name-style="western"><surname>Capo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mege</surname><given-names>J. L.</given-names></name></person-group> (<year>1999</year>). <article-title>IFN-gamma-mediated control of Coxiella burnetii survival in monocytes: the role of cell apoptosis and TNF</article-title>. <source>J. Immunol.</source><volume>162</volume>, <fpage>2259</fpage>&#8211;<lpage>2265</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.162.4.2259</pub-id><pub-id pub-id-type="pmid">9973502</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az-Montero</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Crocquet-Valdes</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Identification of protective components of two major outer membrane proteins of spotted fever group Rickettsiae</article-title>. <source>Am. J. Trop. Med. Hyg</source><volume>65</volume>, <fpage>371</fpage>&#8211;<lpage>378</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.371</pub-id><pub-id pub-id-type="pmid">11693887</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumler</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>1991</year>). <article-title>Clinical and laboratory features of murine typhus in south Texas 1980 through 1987</article-title>. <source>Jama</source><volume>266</volume>, <fpage>1365</fpage>&#8211;<lpage>1370</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.1991.03470100057033</pub-id><pub-id pub-id-type="pmid">1880866</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupont</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hornick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dawkins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heiner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fabrikant</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wisseman</surname><given-names>J. R. ,. C.</given-names></name><etal/></person-group>. (<year>1973</year>). <article-title>Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii</article-title>. <source>J. Infect. Dis.</source><volume>128</volume>, <fpage>340</fpage>&#8211;<lpage>344</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/128.3.340</pub-id><pub-id pub-id-type="pmid">4199563</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyer</surname><given-names>R.</given-names></name></person-group> (<year>1943</year>). <article-title>The menace of typhus in Europe</article-title>. <source>J. Am. Med. Assoc.</source><volume>122</volume>, <fpage>828</fpage>&#8211;<lpage>828</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.1943.02840290048023</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dzul-Rosado</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balam-Romero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valencia-Pacheco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lugo-Caballero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arias-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peniche-Lara</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Immunogenicity of OmpA and OmpB antigens from Rickettsia rickettsii on mononuclear cells from Rickettsia positive Mexican patients</article-title>. <source>J. Vector Borne Dis.</source><volume>54</volume>, <fpage>317</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.4103/0972-9062.225836</pub-id><pub-id pub-id-type="pmid">29460861</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisemann</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Nypaver</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Osterman</surname><given-names>J. V.</given-names></name></person-group> (<year>1984</year>). <article-title>Susceptibility of inbred mice to rickettsiae of the spotted fever group</article-title>. <source>Infection Immun.</source><volume>43</volume>, <fpage>143</fpage>&#8211;<lpage>148</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.43.1.143-148.1984</pub-id><pub-id pub-id-type="pmcid">PMC263401</pub-id><pub-id pub-id-type="pmid">6418657</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisemann</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Osterman</surname><given-names>J. V.</given-names></name></person-group> (<year>1981</year>). <article-title>Antigens of scrub typhus rickettsiae: separation by polyacrylamide gel electrophoresis and identification by enzyme-linked immunosorbent assay</article-title>. <source>Infection Immun.</source><volume>32</volume>, <fpage>525</fpage>&#8211;<lpage>533</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.32.2.525-533.1981</pub-id><pub-id pub-id-type="pmcid">PMC351478</pub-id><pub-id pub-id-type="pmid">6166557</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisen</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Kugeler</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beard</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>C. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Tick-borne zoonoses in the United States: persistent and emerging threats to human health</article-title>. <source>Ilar J.</source><volume>58</volume>, <fpage>319</fpage>&#8211;<lpage>335</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ilar/ilx005</pub-id><pub-id pub-id-type="pmid">28369515</pub-id><pub-id pub-id-type="pmcid">PMC5610605</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenberg George</surname><given-names>H. G.</given-names></name><name name-style="western"><surname>Osterman Joseph</surname><given-names>V.</given-names></name></person-group> (<year>1978</year>). <article-title>Gamma-irradiated scrub typhus immunogens: development and duration of immunity</article-title>. <source>Infection Immun.</source><volume>22</volume>, <fpage>80</fpage>&#8211;<lpage>86</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.22.1.80-86.1978</pub-id><pub-id pub-id-type="pmcid">PMC422119</pub-id><pub-id pub-id-type="pmid">103828</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dahal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>P. N.</given-names></name></person-group> (<year>2019</year>). <article-title>Scrub typhus ecology: a systematic review of Orientia in vectors and hosts</article-title>. <source>Parasites Vectors</source><volume>12</volume>, <fpage>1</fpage>&#8211;<lpage>36</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13071-019-3751-x</pub-id><pub-id pub-id-type="pmid">31685019</pub-id><pub-id pub-id-type="pmcid">PMC6829833</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Embgenbroich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgdorf</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Current concepts of antigen cross-presentation</article-title>. <source>Front. Immunol.</source><volume>9</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01643</pub-id><pub-id pub-id-type="pmcid">PMC6054923</pub-id><pub-id pub-id-type="pmid">30061897</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>1994</year>). <article-title>Depletion of gamma interferon and tumor necrosis factor alpha in mice with Rickettsia conorii-infected endothelium: impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease</article-title>. <source>Infection Immun.</source><volume>62</volume>, <fpage>1952</fpage>&#8211;<lpage>1960</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.62.5.1952-1960.1994</pub-id><pub-id pub-id-type="pmcid">PMC186451</pub-id><pub-id pub-id-type="pmid">8168962</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Cross-protection between distantly related spotted fever group rickettsiae</article-title>. <source>Vaccine</source><volume>21</volume>, <fpage>3901</fpage>&#8211;<lpage>3905</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(03)00301-3</pub-id><pub-id pub-id-type="pmid">12922124</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Whitworth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Olano</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Fc-Dependent Polyclonal Antibodies and Antibodies to Outer Membrane Proteins A and B, but Not to Lipopolysaccharide, Protect SCID Mice against Fatal Rickettsia conorii Infection</article-title>. <source>Infection Immun.</source><volume>72</volume>, <fpage>2222</fpage>&#8211;<lpage>2228</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.72.4.2222-2228.2004</pub-id><pub-id pub-id-type="pmcid">PMC375156</pub-id><pub-id pub-id-type="pmid">15039346</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaxman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Methods for measuring T-cell memory to vaccination: from mouse to man</article-title>. <source>Vaccines</source><volume>6</volume>, <fpage>43</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines6030043</pub-id><pub-id pub-id-type="pmid">30037078</pub-id><pub-id pub-id-type="pmcid">PMC6161152</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>P.-E.</given-names></name><name name-style="western"><surname>Jensenius</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laferl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vene</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>Kinetics of antibody responses in Rickettsia africae and Rickettsia conorii infections</article-title>. <source>Clin. Vaccine Immunol.</source><volume>9</volume>, <fpage>324</fpage>&#8211;<lpage>328</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CDLI.9.2.324-328.2002</pub-id><pub-id pub-id-type="pmcid">PMC119950</pub-id><pub-id pub-id-type="pmid">11874871</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>J. P.</given-names></name></person-group> (<year>1955</year>). <article-title>A review of experience with an avirulent strain of R. prowazeki (strain E) as a living agent for immunizing man against epidemic typhus</article-title>. <source>Am. J. Public Health Nations Health</source><volume>45</volume>, <fpage>1036</fpage>&#8211;<lpage>1048</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2105/AJPH.45.8.1036</pub-id><pub-id pub-id-type="pmid">13238649</pub-id><pub-id pub-id-type="pmcid">PMC1623104</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fratzke</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Van Schaik</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2021</year>a). <article-title>Coxiella burnetii whole cell vaccine produces a th1 delayed-type hypersensitivity response in a novel sensitized mouse model</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <elocation-id>754712</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.754712</pub-id><pub-id pub-id-type="pmid">34616410</pub-id><pub-id pub-id-type="pmcid">PMC8488435</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fratzke</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Jan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Felgner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jasinskas</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>b). <article-title>Subunit vaccines using TLR triagonist combination adjuvants provide protection against coxiella burnetii while minimizing reactogenic responses</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <elocation-id>653092</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.653092</pub-id><pub-id pub-id-type="pmid">33815413</pub-id><pub-id pub-id-type="pmcid">PMC8010241</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fratzke</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Van Schaik</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2022</year>). <article-title>Immunogenicity and reactogenicity in Q fever vaccine development</article-title>. <source>Front. Immunol.</source><volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.886810</pub-id><pub-id pub-id-type="pmcid">PMC9177948</pub-id><pub-id pub-id-type="pmid">35693783</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gidding</surname><given-names>H. F.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Mcintyre</surname><given-names>P. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Australia's national Q fever vaccination program</article-title>. <source>Vaccine</source><volume>27</volume>, <fpage>2037</fpage>&#8211;<lpage>2041</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.007</pub-id><pub-id pub-id-type="pmid">19428827</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilkes</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Albin</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Supnet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tom</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against Coxiella burnetii</article-title>. <source>J. Immunol.</source><volume>204</volume>, <fpage>611</fpage>&#8211;<lpage>621</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1900991</pub-id><pub-id pub-id-type="pmid">31871024</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Hartzell</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Q fever in US military returning from Iraq</article-title>. <source>Am. J. Med.</source><volume>120</volume>, <fpage>e11</fpage>&#8211;<lpage>e12</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.amjmed.2007.03.020</pub-id><pub-id pub-id-type="pmid">17765028</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>a). <article-title>Rickettsia rickettsii outer membrane protein YbgF induces protective immunity in C3H/HeN mice</article-title>. <source>Hum. Vaccines Immunotherapeutics</source><volume>11</volume>, <fpage>642</fpage>&#8211;<lpage>649</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/21645515.2015.1011572</pub-id><pub-id pub-id-type="pmcid">PMC4514262</pub-id><pub-id pub-id-type="pmid">25714655</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>b). <article-title>Enhanced protection against Rickettsia rickettsii infection in C3H/HeN mice by immunization with a combination of a recombinant adhesin rAdr2 and a protein fragment rOmpB-4 derived from outer membrane protein B</article-title>. <source>Vaccine</source><volume>33</volume>, <fpage>985</fpage>&#8211;<lpage>992</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.017</pub-id><pub-id pub-id-type="pmid">25597943</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>a). <article-title>Identification of novel surface-exposed proteins of Rickettsia rickettsii by affinity purification and proteomics</article-title>. <source>PloS One</source><volume>9</volume>, <elocation-id>e100253</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0100253</pub-id><pub-id pub-id-type="pmid">24950252</pub-id><pub-id pub-id-type="pmcid">PMC4065002</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>b). <article-title>Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice</article-title>. <source>Vaccine</source><volume>32</volume>, <fpage>2027</fpage>&#8211;<lpage>2033</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.057</pub-id><pub-id pub-id-type="pmid">24582636</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granoff</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>A. H.</given-names></name></person-group> (<year>1995</year>). <article-title>Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory</article-title>. <source>Ann. New York Acad. Sci.</source><volume>754</volume>, <fpage>278</fpage>&#8211;<lpage>288</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1749-6632.1995.tb44461.x</pub-id><pub-id pub-id-type="pmid">7625664</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Van Schaik</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Fratzke</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Farris</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity</article-title>. <source>Cell Rep. Med.</source><volume>2</volume>, <fpage>100461</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100461</pub-id><pub-id pub-id-type="pmid">35028605</pub-id><pub-id pub-id-type="pmcid">PMC8714860</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grode</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seiler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brinkmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eddine</surname><given-names>A. N.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin</article-title>. <source>J. Clin. Invest.</source><volume>115</volume>, <fpage>2472</fpage>&#8211;<lpage>2479</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI24617</pub-id><pub-id pub-id-type="pmid">16110326</pub-id><pub-id pub-id-type="pmcid">PMC1187936</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-S.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Detection of Antibodies against Orientia tsutsugamushi Sca Proteins in Scrub Typhus Patients and Genetic Variation of sca Genes of Different Strains</article-title>. <source>Clin. Vaccine Immunol.</source><volume>19</volume>, <fpage>1442</fpage>&#8211;<lpage>1451</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00285-12</pub-id><pub-id pub-id-type="pmid">22787193</pub-id><pub-id pub-id-type="pmcid">PMC3428396</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.-S.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Immunization with an Autotransporter Protein of Orientia tsutsugamushi Provides Protective Immunity against Scrub Typhus</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>9</volume>, <elocation-id>e0003585</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0003585</pub-id><pub-id pub-id-type="pmid">25768004</pub-id><pub-id pub-id-type="pmcid">PMC4359152</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackstadt</surname><given-names>T.</given-names></name></person-group> (<year>1988</year>). <article-title>Steric hindrance of antibody binding to surface proteins of Coxiella burnetti by phase I lipopolysaccharide</article-title>. <source>Infect. Immun.</source><volume>56</volume>, <fpage>802</fpage>&#8211;<lpage>807</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.56.4.802-807.1988</pub-id><pub-id pub-id-type="pmid">3346073</pub-id><pub-id pub-id-type="pmcid">PMC259373</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamburg</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Storch</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Micek</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Kollef</surname><given-names>M. H.</given-names></name></person-group> (<year>2008</year>). <article-title>The importance of early treatment with doxycycline in human ehrlichiosis</article-title>. <source>Medicine</source><volume>87</volume> (<issue>2</issue>), <page-range>53&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/MD.0b013e318168da1d</pub-id><pub-id pub-id-type="pmid">18344803</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickman</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Stover</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Oaks</surname><given-names>E. V.</given-names></name></person-group> (<year>1993</year>). <article-title>Murine T-cell response to native and recombinant protein antigens of Rickettsia tsutsugamushi</article-title>. <source>Infection Immun.</source><volume>61</volume>, <fpage>1674</fpage>&#8211;<lpage>1681</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.61.5.1674-1681.1993</pub-id><pub-id pub-id-type="pmcid">PMC280750</pub-id><pub-id pub-id-type="pmid">8478055</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilbink</surname><given-names>F.</given-names></name><name name-style="western"><surname>Penrose</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kovacova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kazar</surname><given-names>J.</given-names></name></person-group> (<year>1993</year>). <article-title>Q fever is absent from New Zealand</article-title>. <source>Int. J. Epidemiol.</source><volume>22</volume>, <fpage>945</fpage>&#8211;<lpage>949</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ije/22.5.945</pub-id><pub-id pub-id-type="pmid">8282477</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilligan</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Ronchese</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses</article-title>. <source>Cell. Mol. Immunol.</source><volume>17</volume>, <fpage>587</fpage>&#8211;<lpage>599</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41423-020-0465-0</pub-id><pub-id pub-id-type="pmid">32433540</pub-id><pub-id pub-id-type="pmcid">PMC7264306</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphres</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Hinrichs</surname><given-names>D. J.</given-names></name></person-group> (<year>1981</year>). <article-title>Role of antibody in Coxiella burnetii infection</article-title>. <source>Infect. Immun.</source><volume>31</volume> (<issue>2</issue>), <page-range>641&#8211;645</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.31.2.641-645.1981</pub-id><pub-id pub-id-type="pmcid">PMC351357</pub-id><pub-id pub-id-type="pmid">7216465</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isken</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Kraaij-Dirkzwager</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermeer-De Bondt</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>R&#252;mke</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Wijkmans</surname><given-names>C.</given-names></name><name name-style="western"><surname>Opstelten</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Implementation of a Q fever vaccination program for high-risk patients in the Netherlands</article-title>. <source>Vaccine</source><volume>31</volume>, <fpage>2617</fpage>&#8211;<lpage>2622</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.03.062</pub-id><pub-id pub-id-type="pmid">23583810</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Tick-borne emerging infections: ehrlichiosis and anaplasmosis</article-title>. <source>Clinics Lab. Med.</source><volume>37</volume>, <fpage>317</fpage>&#8211;<lpage>340</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cll.2017.01.006</pub-id><pub-id pub-id-type="pmid">28457353</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izzo</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Worswick</surname><given-names>D. A.</given-names></name></person-group> (<year>1988</year>). <article-title>Markers of cell-mediated immunity after vaccination with an inactivated, whole-cell Q fever vaccine</article-title>. <source>J. Infect. Dis.</source><volume>157</volume>, <fpage>781</fpage>&#8211;<lpage>789</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/157.4.781</pub-id><pub-id pub-id-type="pmid">3346570</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fratzke</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Felgner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hernandez-Davies</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge</article-title>. <source>Front. Immunol.</source><volume>14</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1192821</pub-id><pub-id pub-id-type="pmcid">PMC10390735</pub-id><pub-id pub-id-type="pmid">37533862</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>A. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Scrub typhus: no longer restricted to the Tsutsugamushi Triangle</article-title>. <source>Trop. Med. Infect. Dis.</source><volume>3</volume>, <fpage>11</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/tropicalmed3010011</pub-id><pub-id pub-id-type="pmid">30274409</pub-id><pub-id pub-id-type="pmcid">PMC6136623</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Mcleod</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Stookey</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Higbee</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>C. E., JR.</given-names></name></person-group> (<year>1977</year>). <article-title>Lesions in Guinea pigs infected with Coxiella burnetii strain M-44</article-title>. <source>J. Infect. Dis.</source><volume>135</volume>, <fpage>995</fpage>&#8211;<lpage>998</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/135.6.995</pub-id><pub-id pub-id-type="pmid">864292</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jw</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hodzic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Magnarelli</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Telford</surname><given-names>S. R., 3RD</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>The early humoral response in human granulocytic ehrlichiosis</article-title>. <source>J. Infect. Dis.</source><volume>176</volume>, <fpage>687</fpage>&#8211;<lpage>692</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1086/514091</pub-id><pub-id pub-id-type="pmid">9291316</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbowiak</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>The occurrence of the Dermacentor reticulatus tick-its expansion to new areas and possible causes</article-title>. <source>Ann. Parasitol.</source><volume>60</volume>.<pub-id pub-id-type="pmid">24930245</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaz&#225;r</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brezina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Palanov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tvrd&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schramek</surname><given-names>S.</given-names></name></person-group> (<year>1982</year>). <article-title>Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in CzechoSlovakia</article-title>. <source>Bull. World Health Organ</source><volume>60</volume>, <fpage>389</fpage>&#8211;<lpage>394</lpage>.<pub-id pub-id-type="pmid">6982774</pub-id><pub-id pub-id-type="pmcid">PMC2536007</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Ching</surname><given-names>W.-M.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>A. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Scrub typhus: the geographic distribution of phenotypic and genotypic variants of Orientia tsutsugamushi</article-title>. <source>Clin. Infect. Dis.</source><volume>48</volume>, <fpage>S203</fpage>&#8211;<lpage>S230</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1086/596576</pub-id><pub-id pub-id-type="pmid">19220144</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenyon</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>JR, C. E.</given-names></name></person-group> (<year>1980</year>). <article-title>Immune responses to Rickettsia akari infection in congenitally athymic nude mice</article-title>. <source>Infection Immun.</source><volume>28</volume>, <fpage>310</fpage>&#8211;<lpage>313</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.28.2.310-313.1980</pub-id><pub-id pub-id-type="pmcid">PMC550934</pub-id><pub-id pub-id-type="pmid">6893190</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenyon</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Sammons</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>C. E., JR.</given-names></name></person-group> (<year>1975</year>). <article-title>Comparison of three rocky mountain spotted fever vaccines</article-title>. <source>J. Clin. Microbiol.</source><volume>2</volume>, <fpage>300</fpage>&#8211;<lpage>304</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jcm.2.4.300-304.1975</pub-id><pub-id pub-id-type="pmid">810494</pub-id><pub-id pub-id-type="pmcid">PMC362799</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khanzada</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jalal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>R.</given-names></name></person-group> (<year>2023</year>). <article-title>Integrating core subtractive proteomics and reverse vaccinology for multi-epitope vaccine design against Rickettsia prowazekii endemic typhus</article-title>. <source>Immunologic Res</source>. <volume>72</volume> (<issue>1</issue>), <page-range>82&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12026-023-09415-y</pub-id><pub-id pub-id-type="pmid">37608125</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Saifullah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mallhi</surname><given-names>T. H.</given-names></name></person-group> (<year>2022</year>). &#8220;<article-title>Bacterial vaccines</article-title>,&#8221; in <source>Encyclopedia of Infection and Immunity</source>. Ed. <person-group person-group-type="editor"><name name-style="western"><surname>REZAEI</surname><given-names>N.</given-names></name></person-group> (<publisher-name>Elsevier</publisher-name>, <publisher-loc>Oxford</publisher-loc>).</mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>N.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Min</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>N. T. H.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Immunization with a recombinant antigen composed of conserved blocks from TSA56 provides broad genotype protection against scrub typhus</article-title>. <source>Emerging Microbes Infections</source><volume>8</volume>, <fpage>946</fpage>&#8211;<lpage>958</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/22221751.2019.1632676</pub-id><pub-id pub-id-type="pmid">31237478</pub-id><pub-id pub-id-type="pmcid">PMC6598529</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>O. Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W. H.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses</article-title>. <source>J. Immunol.</source><volume>190</volume>, <fpage>4092</fpage>&#8211;<lpage>4102</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1200742</pub-id><pub-id pub-id-type="pmid">23514742</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group> (<year>1998</year>). <article-title>Characterization of monoclonal antibodies to the 44-kilodalton major outer membrane protein of the human granulocytic ehrlichiosis agent</article-title>. <source>J. Clin. Microbiol.</source><volume>36</volume>, <fpage>3278</fpage>&#8211;<lpage>3284</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/JCM.36.11.3278-3284.1998</pub-id><pub-id pub-id-type="pmid">9774579</pub-id><pub-id pub-id-type="pmcid">PMC105315</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishimoto</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J. S.</given-names></name></person-group> (<year>1976</year>). <article-title>Interaction between Coxiella burnetii and Guinea pig peritoneal macrophages</article-title>. <source>Infect. Immun.</source><volume>14</volume>, <fpage>416</fpage>&#8211;<lpage>421</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.14.2.416-421.1976</pub-id><pub-id pub-id-type="pmid">971955</pub-id><pub-id pub-id-type="pmcid">PMC420900</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovalchik</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Wessling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saab</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Despault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kubiniok</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Immunopeptidomics for dummies: detailed experimental protocols and rapid, user-friendly visualization of MHC I and II ligand datasets with mhcVizPipe</article-title>. <source>bioRxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2020.11.02.360958</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalzik</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schreiner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teschner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gehring</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zepp</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>mRNA-based vaccines</article-title>. <source>Vaccines</source><volume>9</volume>, <fpage>390</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9040390</pub-id><pub-id pub-id-type="pmid">33921028</pub-id><pub-id pub-id-type="pmcid">PMC8103517</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuwata</surname><given-names>T.</given-names></name></person-group> (<year>1952</year>). <article-title>Analysis of immunity in experimental tsutsugamushi disease</article-title>. <source>J. Immunol.</source><volume>68</volume>, <fpage>115</fpage>&#8211;<lpage>120</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.68.2.115</pub-id><pub-id pub-id-type="pmid">14927917</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lackman</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Pickens</surname><given-names>E. G.</given-names></name></person-group> (<year>1962</year>). <article-title>Intradermal sensitivity testing in man with a purified vaccine for Q fever</article-title>. <source>Am. J. Public Health Nations Health</source><volume>52</volume>, <fpage>87</fpage>&#8211;<lpage>93</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2105/AJPH.52.1.87</pub-id><pub-id pub-id-type="pmid">14461400</pub-id><pub-id pub-id-type="pmcid">PMC1522671</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Trisal</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine</article-title>. <source>Nat. Immunol.</source><volume>23</volume>, <fpage>543</fpage>&#8211;<lpage>555</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41590-022-01163-9</pub-id><pub-id pub-id-type="pmid">35288714</pub-id><pub-id pub-id-type="pmcid">PMC8989677</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The immunoregulation of th17 in host against intracellular bacterial infection</article-title>. <source>Mediators Inflammation</source><volume>2018</volume>, <fpage>6587296</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2018/6587296</pub-id><pub-id pub-id-type="pmcid">PMC5884031</pub-id><pub-id pub-id-type="pmid">29743811</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lightman</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Utley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Survival of long-lived plasma cells (LLPC): piecing together the puzzle</article-title>. <source>Front. Immunol.</source><volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00965</pub-id><pub-id pub-id-type="pmcid">PMC6510054</pub-id><pub-id pub-id-type="pmid">31130955</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Beare</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Fintzi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tesfamariam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shaia</surname><given-names>C. I.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity</article-title>. <source>NPJ Vaccines</source><volume>6</volume>, <fpage>38</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-021-00296-6</pub-id><pub-id pub-id-type="pmid">33741986</pub-id><pub-id pub-id-type="pmcid">PMC7979919</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotric-Furlan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avsic-Zupanc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Petrovec</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Childs</surname><given-names>J. E.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia</article-title>. <source>Clin. Diagn. Lab. Immunol.</source><volume>8</volume>, <fpage>899</fpage>&#8211;<lpage>903</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CDLI.8.5.899-903.2001</pub-id><pub-id pub-id-type="pmid">11527800</pub-id><pub-id pub-id-type="pmcid">PMC96168</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luce-Fedrow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maina</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>R. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>A review of scrub typhus (Orientia tsutsugamushi and related organisms): then, now, and tomorrow</article-title>. <source>Trop. Med. Infect. Dis.</source><volume>3</volume> (<issue>1</issue>), <fpage>8</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/tropicalmed3010008</pub-id><pub-id pub-id-type="pmid">30274407</pub-id><pub-id pub-id-type="pmcid">PMC6136631</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes</article-title>. <source>NPJ Vaccines</source><volume>5</volume>, <fpage>85</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-020-00231-1</pub-id><pub-id pub-id-type="pmid">32963815</pub-id><pub-id pub-id-type="pmcid">PMC7486380</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Patel Jignesh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Walker David</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mcbride Jere</surname><given-names>W.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunoreactive Protein Repertoires of Ehrlichia chaffeensis and E. canis Reveal the Dominance of Hypothetical Proteins and Conformation-Dependent Antibody Epitopes</article-title>. <source>Infection Immun.</source><volume>89</volume>, <fpage>e00224</fpage>&#8211;<lpage>e00221</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00224-21</pub-id><pub-id pub-id-type="pmcid">PMC8519286</pub-id><pub-id pub-id-type="pmid">34370510</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Major species-specific antibody epitopes of the Ehrlichia chaffeensis p120 and E. canis p140 orthologs in surface-exposed tandem repeat regions</article-title>. <source>Clin. Vaccine Immunol.</source><volume>16</volume>, <fpage>982</fpage>&#8211;<lpage>990</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00048-09</pub-id><pub-id pub-id-type="pmid">19420187</pub-id><pub-id pub-id-type="pmcid">PMC2708412</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Molecular characterization of antibody epitopes of Ehrlichia chaffeensis ankyrin protein 200 and tandem repeat protein 47 and evaluation of synthetic immunodeterminants for serodiagnosis of human monocytotropic ehrlichiosis</article-title>. <source>Clin. Vaccine Immunol.</source><volume>17</volume>, <fpage>87</fpage>&#8211;<lpage>97</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00331-09</pub-id><pub-id pub-id-type="pmid">19955322</pub-id><pub-id pub-id-type="pmcid">PMC2812101</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name></person-group> (<year>1967</year>). <article-title>Development of Q-fever vaccines 1937 to 1967</article-title>. <source>Med. J. Aust.</source><volume>2</volume>, <fpage>1074</fpage>&#8211;<lpage>1078</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.5694/j.1326-5377.1967.tb27293.x</pub-id><pub-id pub-id-type="pmid">4864428</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Ormsbee</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Kyrkou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.</given-names></name><name name-style="western"><surname>Worswick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>1984</year>). <article-title>Vaccine prophylaxis of abattoir-associated Q fever</article-title>. <source>Lancet</source><volume>2</volume>, <fpage>1411</fpage>&#8211;<lpage>1414</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(84)91617-9</pub-id><pub-id pub-id-type="pmid">6151039</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Ormsbee</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Kyrkou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.</given-names></name><name name-style="western"><surname>Worswick</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Izzo</surname><given-names>A. A.</given-names></name><etal/></person-group>. (<year>1990</year>). <article-title>Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs</article-title>. <source>Epidemiol. Infect.</source><volume>104</volume> (<issue>2</issue>), <page-range>275&#8211;287</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1017/S0950268800059458</pub-id><pub-id pub-id-type="pmcid">PMC2271744</pub-id><pub-id pub-id-type="pmid">2323360</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masignani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moxon</surname><given-names>E. R.</given-names></name></person-group> (<year>2019</year>). <article-title>The development of a vaccine against meningococcus B using reverse vaccinology</article-title>. <source>Front. Immunol.</source><volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00751</pub-id><pub-id pub-id-type="pmcid">PMC6477034</pub-id><pub-id pub-id-type="pmid">31040844</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Seligmann JR</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>R. K.</given-names></name></person-group> (<year>1976</year>). <article-title>A reference, inactivated, epidemic typhus vaccine: clinical trials in man</article-title>. <source>J. Biol. standardization</source><volume>4</volume>, <fpage>217</fpage>&#8211;<lpage>224</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0092-1157(76)80006-6</pub-id><pub-id pub-id-type="pmid">820697</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>1999</year>). <article-title>Q fever</article-title>. <source>Clin. Microbiol. Rev.</source><volume>12</volume>, <fpage>518</fpage>&#8211;<lpage>553</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CMR.12.4.518</pub-id><pub-id pub-id-type="pmid">10515901</pub-id><pub-id pub-id-type="pmcid">PMC88923</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Impens</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunopeptidomics for next-generation bacterial vaccine development</article-title>. <source>Trends Microbiol.</source><volume>29</volume>, <fpage>1034</fpage>&#8211;<lpage>1045</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tim.2021.04.010</pub-id><pub-id pub-id-type="pmid">34030969</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcclure</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Ch&#225;vez</surname><given-names>A. S. O.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Carlyon</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ganta</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Engineering of obligate intracellular bacteria: progress, challenges and paradigms</article-title>. <source>Nat. Rev. Microbiol.</source><volume>15</volume>, <fpage>544</fpage>&#8211;<lpage>558</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro.2017.59</pub-id><pub-id pub-id-type="pmid">28626230</pub-id><pub-id pub-id-type="pmcid">PMC5557331</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcelrath</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kierstead</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case&#8211;cohort analysis</article-title>. <source>Lancet</source><volume>372</volume>, <fpage>1894</fpage>&#8211;<lpage>1905</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(08)61592-5</pub-id><pub-id pub-id-type="pmid">19012957</pub-id><pub-id pub-id-type="pmcid">PMC2774110</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcgill</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A. D. S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rusk</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Ganta</surname><given-names>R. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Vaccination with an attenuated mutant of ehrlichia chaffeensis induces pathogen-specific CD4+ T cell immunity and protection from tick-transmitted wild-type challenge in the canine host</article-title>. <source>PloS One</source><volume>11</volume>, <elocation-id>e0148229</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0148229</pub-id><pub-id pub-id-type="pmid">26841025</pub-id><pub-id pub-id-type="pmcid">PMC4739596</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moderzynski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuehl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richardt</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Cytotoxic effector functions of T cells are not required for protective immunity against fatal Rickettsia typhi infection in a murine model of infection: Role of TH1 and TH17 cytokines in protection and pathology</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>11</volume>, <elocation-id>e0005404</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0005404</pub-id><pub-id pub-id-type="pmid">28222146</pub-id><pub-id pub-id-type="pmcid">PMC5336310</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moderzynski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuehl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richardt</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>CD4+ T cells are as protective as CD8+ T cells against Rickettsia typhi infection by activating macrophage bactericidal activity</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>10</volume>, <elocation-id>e0005089</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0005089</pub-id><pub-id pub-id-type="pmid">27875529</pub-id><pub-id pub-id-type="pmcid">PMC5119731</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naimi Waheeda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gumpf Jacob</surname><given-names>J.</given-names></name><name name-style="western"><surname>Green Ryan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Izac Jerilyn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zellner Matthew</surname><given-names>P.</given-names></name><name name-style="western"><surname>Conrad Daniel</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Immunization against Anaplasma phagocytophilum Adhesin Binding Domains Confers Protection against Infection in the Mouse Model</article-title>. <source>Infection Immun.</source><volume>88</volume>, <fpage>e00106</fpage>&#8211;<lpage>e00120</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00106-20</pub-id><pub-id pub-id-type="pmcid">PMC7504939</pub-id><pub-id pub-id-type="pmid">32661123</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>A. D. S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Ganta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Ganta</surname><given-names>R. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Attenuated Mutants of Ehrlichia chaffeensis Induce Protection against Wild-Type Infection Challenge in the Reservoir Host and in an Incidental Host</article-title>. <source>Infection Immun.</source><volume>83</volume>, <fpage>2827</fpage>&#8211;<lpage>2835</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00487-15</pub-id><pub-id pub-id-type="pmcid">PMC4468539</pub-id><pub-id pub-id-type="pmid">25916990</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hogle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vitko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Winslow</surname><given-names>G. M.</given-names></name></person-group> (<year>2007</year>). <article-title>CD4 T-cell epitopes associated with protective immunity induced following vaccination of mice with an ehrlichial variable outer membrane protein</article-title>. <source>Infection Immun.</source><volume>75</volume>, <fpage>5453</fpage>&#8211;<lpage>5459</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00713-07</pub-id><pub-id pub-id-type="pmcid">PMC2168300</pub-id><pub-id pub-id-type="pmid">17698576</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narasimhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kurokawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deblasio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sajid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Acquired tick resistance: The trail is hot</article-title>. <source>Parasite Immunol.</source><volume>43</volume>, <elocation-id>e12808</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1111/pim.12808</pub-id><pub-id pub-id-type="pmid">33187012</pub-id><pub-id pub-id-type="pmcid">PMC8058238</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>N. D. N. T.</given-names></name><name name-style="western"><surname>Guleed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With Chlamydia trachomatis</article-title>. <source>Front. Immunol.</source><volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.790463</pub-id><pub-id pub-id-type="pmcid">PMC8674352</pub-id><pub-id pub-id-type="pmid">34925371</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuizen</surname><given-names>N. E.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Shaligram</surname><given-names>U.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Eisele</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>The recombinant bacille calmette-gu&#233;rin vaccine VPM1002: ready for clinical efficacy testing</article-title>. <source>Front. Immunol.</source><volume>8</volume>, <elocation-id>1147</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01147</pub-id><pub-id pub-id-type="pmid">28974949</pub-id><pub-id pub-id-type="pmcid">PMC5610719</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oaks</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Stover</surname><given-names>C. K.</given-names></name></person-group> (<year>1989</year>). <article-title>Antigenic and genetic relatedness of eight Rickettsia tsutsugamushi antigens</article-title>. <source>Infect. Immun.</source><volume>57</volume>, <fpage>3116</fpage>&#8211;<lpage>3122</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.57.10.3116-3122.1989</pub-id><pub-id pub-id-type="pmid">2476399</pub-id><pub-id pub-id-type="pmcid">PMC260778</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunjimi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beutels</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>UK experience of herpes zoster vaccination can inform varicella zoster virus policies</article-title>. <source>Lancet Public Health</source><volume>3</volume>, <fpage>e57</fpage>&#8211;<lpage>e58</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2468-2667(17)30245-1</pub-id><pub-id pub-id-type="pmid">29276016</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Unver</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group> (<year>1998</year>). <article-title>Cloning and characterization of multigenes encoding the immunodominant 30-kilodalton major outer membrane proteins of Ehrlichia canis and application of the recombinant protein for serodiagnosis</article-title>. <source>J. Clin. Microbiol.</source><volume>36</volume>, <fpage>2671</fpage>&#8211;<lpage>2680</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/JCM.36.9.2671-2680.1998</pub-id><pub-id pub-id-type="pmid">9705412</pub-id><pub-id pub-id-type="pmcid">PMC105182</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olatunde</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>T. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Cytokine-skewed Tfh cells: functional consequences for B cell help</article-title>. <source>Trends Immunol.</source><volume>42</volume>, <fpage>536</fpage>&#8211;<lpage>550</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.it.2021.04.006</pub-id><pub-id pub-id-type="pmid">33972167</pub-id><pub-id pub-id-type="pmcid">PMC9107098</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omsland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Virtaneva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sturdevant</surname><given-names>D. E.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Host cell-free growth of the Q fever bacterium Coxiella burnetii</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>106</volume>, <fpage>4430</fpage>&#8211;<lpage>4434</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0812074106</pub-id><pub-id pub-id-type="pmid">19246385</pub-id><pub-id pub-id-type="pmcid">PMC2657411</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osterloh</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Immune response against rickettsiae: lessons from murine infection models</article-title>. <source>Med. Microbiol. Immunol.</source><volume>206</volume>, <fpage>403</fpage>&#8211;<lpage>417</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00430-017-0514-1</pub-id><pub-id pub-id-type="pmid">28770333</pub-id><pub-id pub-id-type="pmcid">PMC5664416</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Intranasal Vaccination with Outer-Membrane Protein of Orientia tsutsugamushi induces Protective Immunity Against Scrub Typhus</article-title>. <source>Immune Netw.</source><volume>21</volume>, <elocation-id>e14</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.4110/in.2021.21.e14</pub-id><pub-id pub-id-type="pmid">33996170</pub-id><pub-id pub-id-type="pmcid">PMC8099613</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvizpour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pourseif</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Razmara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rafi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches</article-title>. <source>Drug Discovery Today</source><volume>25</volume>, <fpage>1034</fpage>&#8211;<lpage>1042</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.drudis.2020.03.006</pub-id><pub-id pub-id-type="pmid">32205198</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philip</surname><given-names>C. B.</given-names></name></person-group> (<year>1948</year>). <article-title>Tsutsugamushi disease (Scrub typhus) in world war II</article-title>. <source>J. Parasitol.</source><volume>34</volume>, <fpage>169</fpage>&#8211;<lpage>191</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2307/3273264</pub-id><pub-id pub-id-type="pmid">18867393</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Complex correlates of protection after vaccination</article-title>. <source>Clin. Infect. Dis.</source><volume>56</volume>, <fpage>1458</fpage>&#8211;<lpage>1465</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/cit048</pub-id><pub-id pub-id-type="pmid">23386629</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>P. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Nomenclature for immune correlates of protection after vaccination</article-title>. <source>Clin. Infect. Dis.</source><volume>54</volume>, <fpage>1615</fpage>&#8211;<lpage>1617</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/cis238</pub-id><pub-id pub-id-type="pmid">22437237</pub-id><pub-id pub-id-type="pmcid">PMC3348952</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pawlikowska-&#321;ag&#243;d</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zagaja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grzybowski</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Typhus works of Rudolf Weigl, PhD, Ludwik Fleck, MD, and Eugeniusz &#321;azowski, MD, against the Nazis</article-title>. <source>Clinics Dermatol.</source><volume>40</volume>, <fpage>567</fpage>&#8211;<lpage>572</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clindermatol.2022.02.016</pub-id><pub-id pub-id-type="pmid">35182710</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;hagan</surname><given-names>D. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat. Rev. Drug Discovery</source><volume>20</volume>, <fpage>454</fpage>&#8211;<lpage>475</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name></person-group> (<year>2013</year>a). <article-title>Recombinant protein YbgF induces protective immunity against Rickettsia heilongjiangensis infection in C3H/HeN mice</article-title>. <source>Vaccine</source><volume>31</volume>, <fpage>5643</fpage>&#8211;<lpage>5650</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.064</pub-id><pub-id pub-id-type="pmid">24113261</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>b). <article-title>Proteome analysis and serological characterization of surface-exposed proteins of rickettsia heilongjiangensis</article-title>. <source>PloS One</source><volume>8</volume>, <elocation-id>e70440</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0070440</pub-id><pub-id pub-id-type="pmid">23894656</pub-id><pub-id pub-id-type="pmcid">PMC3720918</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappazzo</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Delisa</surname><given-names>M. P.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice</article-title>. <source>Vaccine</source><volume>34</volume>, <fpage>1252</fpage>&#8211;<lpage>1258</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.028</pub-id><pub-id pub-id-type="pmid">26827663</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Reverse vaccinology</article-title>. <source>Curr. Opin. Microbiol.</source><volume>3</volume>, <fpage>445</fpage>&#8211;<lpage>450</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1369-5274(00)00119-3</pub-id><pub-id pub-id-type="pmid">11050440</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Read</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>A. G.</given-names></name></person-group> (<year>2010</year>). <article-title>Role of CD4(+) and CD8(+) T cells in clearance of primary pulmonary infection with coxiella burnetii</article-title>. <source>Infection Immun.</source><volume>78</volume>, <fpage>3019</fpage>&#8211;<lpage>3026</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00101-10</pub-id><pub-id pub-id-type="pmcid">PMC2897389</pub-id><pub-id pub-id-type="pmid">20351144</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhinehart-Jones</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Fortier</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>K. L.</given-names></name></person-group> (<year>1994</year>). <article-title>Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells</article-title>. <source>Infection Immun.</source><volume>62</volume>, <fpage>3129</fpage>&#8211;<lpage>3137</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.62.8.3129-3137.1994</pub-id><pub-id pub-id-type="pmcid">PMC302937</pub-id><pub-id pub-id-type="pmid">8039881</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>A. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Rickettsial vaccines: the old and the new</article-title>. <source>Expert Rev. Vaccines</source><volume>3</volume>, <fpage>541</fpage>&#8211;<lpage>555</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14760584.3.5.541</pub-id><pub-id pub-id-type="pmid">15485334</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Anaplasma phagocytophilum and Ehrlichia chaffeensis: subversive manipulators of host cells</article-title>. <source>Nat. Rev. Microbiol.</source><volume>8</volume>, <fpage>328</fpage>&#8211;<lpage>339</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro2318</pub-id><pub-id pub-id-type="pmid">20372158</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Rustigian</surname><given-names>R.</given-names></name></person-group> (<year>1946</year>). <article-title>Q fever in the Mediterranean area; report of its occurrence in Allied troops; a laboratory outbreak</article-title>. <source>Am. J. Hyg</source><volume>44</volume>, <fpage>64</fpage>&#8211;<lpage>71</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a119085</pub-id><pub-id pub-id-type="pmid">20994100</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Hasty</surname><given-names>S. E.</given-names></name></person-group> (<year>1974</year>). <article-title>Production of a potent vaccine from the attenuated M-44 strain of Coxiella burneti</article-title>. <source>Appl. Microbiol.</source><volume>27</volume>, <fpage>777</fpage>&#8211;<lpage>783</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/am.27.4.777-783.1974</pub-id><pub-id pub-id-type="pmid">4825980</pub-id><pub-id pub-id-type="pmcid">PMC380134</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolain</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>2005</year>). <article-title>Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline</article-title>. <source>Ann. N Y Acad. Sci.</source><volume>1063</volume>, <fpage>252</fpage>&#8211;<lpage>256</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1196/annals.1355.039</pub-id><pub-id pub-id-type="pmid">16481522</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rousset</surname><given-names>E.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Prigent</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Forfait</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Efficiency of a phase 1 vaccine for the reduction of vaginal Coxiella burnetii shedding in a clinically affected goat herd</article-title>. <source>Clin. Microbiol. Infect.</source><volume>15 Suppl 2</volume>, <fpage>188</fpage>&#8211;<lpage>189</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.02220.x</pub-id><pub-id pub-id-type="pmid">19793119</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Riddle</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Mohareb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Monteville</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Faix</surname><given-names>D. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Seroepidemiologic survey for coxiella burnetii among US military personnel deployed to southwest and central asia in 2005</article-title>. <source>Am. J. Trop. Med. Hygiene</source><volume>89</volume>, <fpage>991</fpage>&#8211;<lpage>995</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4269/ajtmh.12-0174</pub-id><pub-id pub-id-type="pmcid">PMC3820350</pub-id><pub-id pub-id-type="pmid">24043692</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruang-Areerate</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jeamwattanalert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodkvamtook</surname><given-names>W.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Sunyakumthorn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gaywee</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Genotype diversity and distribution of orientia tsutsugamushi causing scrub typhus in Thailand</article-title>. <source>J. Clin. Microbiol.</source><volume>49</volume>, <fpage>2584</fpage>&#8211;<lpage>2589</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/JCM.00355-11</pub-id><pub-id pub-id-type="pmid">21593255</pub-id><pub-id pub-id-type="pmcid">PMC3147819</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poels</surname><given-names>M. W. J.</given-names></name><name name-style="western"><surname>Shive</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G. Q.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Coxiella burnetii isolates cause genogroup-specific virulence in mouse and Guinea pig models of acute Q fever</article-title>. <source>Infection Immun.</source><volume>77</volume>, <fpage>5640</fpage>&#8211;<lpage>5650</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00851-09</pub-id><pub-id pub-id-type="pmcid">PMC2786457</pub-id><pub-id pub-id-type="pmid">19786560</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noori Goodarzi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haririzadeh Jouriani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bolourchi</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Genome-wide subtraction analysis and reverse vaccinology to detect novel drug targets and potential vaccine candidates against ehrlichia chaffeensis</article-title>. <source>Appl. Biochem. Biotechnol.</source><volume>195</volume>, <fpage>107</fpage>&#8211;<lpage>124</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12010-022-04116-y</pub-id><pub-id pub-id-type="pmid">36053401</pub-id><pub-id pub-id-type="pmcid">PMC9437403</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sajid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kurokawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deponte</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent</article-title>. <source>Sci. Trans. Med.</source><volume>13</volume>, <elocation-id>eabj9827</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.abj9827</pub-id><pub-id pub-id-type="pmid">34788080</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sershen</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>May</surname><given-names>E. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Investigating the role of TNF-&#945; and IFN-&#947; activation on the dynamics of iNOS gene expression in LPS stimulated macrophages</article-title>. <source>PloS One</source><volume>11</volume>, <elocation-id>e0153289</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0153289</pub-id><pub-id pub-id-type="pmid">27276061</pub-id><pub-id pub-id-type="pmcid">PMC4898755</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salje</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Cells within cells: Rickettsiales and the obligate intracellular bacterial lifestyle</article-title>. <source>Nat. Rev. Microbiol.</source><volume>19</volume>, <fpage>375</fpage>&#8211;<lpage>390</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41579-020-00507-2</pub-id><pub-id pub-id-type="pmid">33564174</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schramek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brezina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Visack&#225;</surname><given-names>E.</given-names></name></person-group> (<year>1983</year>). <article-title>Different antigenic properties of lipopolysaccharides isolated from Coxiella burnetii in phase I and pure phase II</article-title>. <source>Zentralbl Bakteriol Mikrobiol Hyg A Med. Mikrobiol Infekt Parasitol.</source><volume>255</volume>, <fpage>356</fpage>&#8211;<lpage>360</lpage>.<pub-id pub-id-type="pmid">6417946</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seidman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hebert</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Truchan</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Tegels</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>R. T.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Essential domains of Anaplasma phagocytophilum invasins utilized to infect mammalian host cells</article-title>. <source>PloS Pathog.</source><volume>11</volume>, <elocation-id>e1004669</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1004669</pub-id><pub-id pub-id-type="pmid">25658707</pub-id><pub-id pub-id-type="pmcid">PMC4450072</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bosward</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Willis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cobbold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Comeau</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Frequency of adverse events following Q fever immunisation in young adults</article-title>. <source>Vaccines (Basel)</source><volume>6</volume> (<issue>4</issue>), <fpage>83</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines6040083</pub-id><pub-id pub-id-type="pmid">30551615</pub-id><pub-id pub-id-type="pmcid">PMC6313871</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seong</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>S. G.</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>Induction of homologous immune response to Rickettsia tsutsugamushi Boryong with a partial 56-kilodalton recombinant antigen fused with the maltose-binding protein MBP-Bor56</article-title>. <source>Infection Immun.</source><volume>65</volume>, <fpage>1541</fpage>&#8211;<lpage>1545</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.65.4.1541-1545.1997</pub-id><pub-id pub-id-type="pmcid">PMC175167</pub-id><pub-id pub-id-type="pmid">9119501</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Heinzen</surname><given-names>R. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Antibody-mediated immunity to the obligate intracellular bacterial pathogen Coxiella burnetii is Fc receptor- and complement-independent</article-title>. <source>BMC Immunol.</source><volume>10</volume>, <fpage>26</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-2172-10-26</pub-id><pub-id pub-id-type="pmid">19426498</pub-id><pub-id pub-id-type="pmcid">PMC2689861</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heinzen</surname><given-names>R. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>1063</volume>, <page-range>154&#8211;160</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1196/annals.1355.024</pub-id><pub-id pub-id-type="pmcid">PMC1150828</pub-id><pub-id pub-id-type="pmid">15939879</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu-Yi Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yager</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>A. A.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen ehrlichia chaffeensis1</article-title>. <source>J. Immunol.</source><volume>166</volume>, <fpage>1855</fpage>&#8211;<lpage>1862</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.166.3.1855</pub-id><pub-id pub-id-type="pmid">11160232</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smadel</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>H. L. J. R.</given-names></name><name name-style="western"><surname>Diercks</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Traub</surname><given-names>R.</given-names></name></person-group> (<year>1950</year>). <article-title>Immunity in scrub typhus : resistance to induced reinfection</article-title>. <source>Arch. Pathol.</source><volume>50</volume>, <fpage>847</fpage>&#8211;<lpage>861</lpage>.<pub-id pub-id-type="pmid">14789327</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Smadel</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>F. C.</given-names></name></person-group> (<year>1947</year>). <article-title>Vaccination against Q fever</article-title>. <source>J. Bacteriol</source><volume>54</volume>, <fpage>77</fpage>.<pub-id pub-id-type="pmid">20344306</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonenshine</surname><given-names>D. E.</given-names></name></person-group> (<year>2018</year>). <article-title>Range expansion of tick disease vectors in North America: implications for spread of tick-borne disease</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>15</volume> (<issue>3</issue>), <fpage>478</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijerph15030478</pub-id><pub-id pub-id-type="pmid">29522469</pub-id><pub-id pub-id-type="pmcid">PMC5877023</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R.</given-names></name></person-group> (<year>1925</year>). <article-title>Rocky Mountain spotted fever: vaccination of monkeys and man</article-title>. <source>Public Health Rep.</source><volume>40</volume>, <fpage>2159</fpage>&#8211;<lpage>2167</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2307/4577679</pub-id>
19315003
</mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stary</surname><given-names>G.</given-names></name><name name-style="western"><surname>Olive</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radovic-Moreno</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Gondek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Basto</surname><given-names>P. A.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells</article-title>. <source>Science</source><volume>348</volume>, <fpage>aaa8205</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.aaa8205</pub-id><pub-id pub-id-type="pmid">26089520</pub-id><pub-id pub-id-type="pmcid">PMC4605428</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoker</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Fiset</surname><given-names>P.</given-names></name></person-group> (<year>1956</year>). <article-title>Phase variation of the Nine Mile and other strains of Rickettsia burneti</article-title>. <source>Can. J. Microbiol.</source><volume>2</volume>, <fpage>310</fpage>&#8211;<lpage>321</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1139/m56-036</pub-id><pub-id pub-id-type="pmid">13316625</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strickman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Salata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hershey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dasch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>1995</year>). <article-title>
<italic toggle="yes">In vitro</italic> effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>39</volume>, <fpage>2406</fpage>&#8211;<lpage>2410</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/AAC.39.11.2406</pub-id><pub-id pub-id-type="pmid">8585717</pub-id><pub-id pub-id-type="pmcid">PMC162956</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jw</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Telford</surname><given-names>S. R. 3RD</given-names></name><name name-style="western"><surname>Hodzic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barthold</surname><given-names>S. W.</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>Immunization against the agent of human granulocytic ehrlichiosis in a murine model</article-title>. <source>J. Clin. Invest.</source><volume>100</volume>, <fpage>3014</fpage>&#8211;<lpage>3018</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI119855</pub-id><pub-id pub-id-type="pmid">9399947</pub-id><pub-id pub-id-type="pmcid">PMC508513</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesfamariam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Binette</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beare</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Heinzen</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Shaia</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Characterization of coxiella burnetii dugway strain host-pathogen interactions <italic toggle="yes">in vivo</italic>
</article-title>. <source>Microorganisms</source><volume>10</volume> (<issue>11</issue>), <fpage>2261</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/microorganisms10112261</pub-id><pub-id pub-id-type="pmid">36422331</pub-id><pub-id pub-id-type="pmcid">PMC9692954</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikkelsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jungersen</surname><given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Intracellular pathogens: host immunity and microbial persistence strategies</article-title>. <source>J. Immunol. Res.</source><volume>2019</volume>, <fpage>1356540</fpage>&#8211;<lpage>1356540</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2019/1356540</pub-id><pub-id pub-id-type="pmid">31111075</pub-id><pub-id pub-id-type="pmcid">PMC6487120</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thirumalapura</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Crocquet-Valdes</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Recombinant Ehrlichia P29 protein induces a protective immune response in a mouse model of ehrlichiosis</article-title>. <source>Vaccine</source><volume>31</volume>, <fpage>5960</fpage>&#8211;<lpage>5967</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.036</pub-id><pub-id pub-id-type="pmid">24144475</pub-id><pub-id pub-id-type="pmcid">PMC3893061</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Lidbury</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Antibody-dependent enhancement and vaccine development</article-title>. <source>Expert Rev. Vaccines</source><volume>5</volume>, <fpage>409</fpage>&#8211;<lpage>412</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14760584.5.4.409</pub-id><pub-id pub-id-type="pmid">16989620</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thirumalapura</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Crocquet-Valdes</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Luxon</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Structure-based vaccines provide protection in a mouse model of ehrlichiosis</article-title>. <source>PloS One</source><volume>6</volume>, <elocation-id>e27981</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0027981</pub-id><pub-id pub-id-type="pmid">22114733</pub-id><pub-id pub-id-type="pmcid">PMC3219711</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Echeverria-Londono</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Clapham</surname><given-names>H. E.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world</article-title>. <source>eLife</source><volume>10</volume>, <elocation-id>e67635</elocation-id>.<pub-id pub-id-type="pmid">34253291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.67635</pub-id><pub-id pub-id-type="pmcid">PMC8277373</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trager</surname><given-names>W.</given-names></name></person-group> (<year>1939</year>). <article-title>Acquired immunity to ticks</article-title>. <source>J. Parasitol.</source><volume>25</volume>, <fpage>57</fpage>&#8211;<lpage>81</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2307/3272160</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>La Gruta</surname><given-names>N. L.</given-names></name></person-group> (<year>2021</year>). <article-title>CD8(+) T-cell memory: the why, the when, and the how</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source><volume>13</volume> (<issue>5</issue>), <fpage>a038661</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1101/cshperspect.a038661</pub-id><pub-id pub-id-type="pmid">33648987</pub-id><pub-id pub-id-type="pmcid">PMC8091951</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanaja</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Behl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yankova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>S. D.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation</article-title>. <source>Cell</source><volume>165</volume>, <fpage>1106</fpage>&#8211;<lpage>1119</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2016.04.015</pub-id><pub-id pub-id-type="pmid">27156449</pub-id><pub-id pub-id-type="pmcid">PMC4874922</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques</article-title>. <source>Sci. Adv.</source><volume>6</volume>, <elocation-id>eaba8399</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.aba8399</pub-id><pub-id pub-id-type="pmid">32577525</pub-id><pub-id pub-id-type="pmcid">PMC7286676</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Schaik</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Case</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bonazzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2017</year>). <article-title>The SCID mouse model for identifying virulence determinants in coxiella burnetii</article-title>. <source>Front. Cell. Infection Microbiol.</source><volume>7</volume>, <elocation-id>25</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00025</pub-id><pub-id pub-id-type="pmcid">PMC5289997</pub-id><pub-id pub-id-type="pmid">28217558</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Schaik</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Molecular pathogenesis of the obligate intracellular bacterium Coxiella burnetii</article-title>. <source>Nat. Rev. Micro</source><volume>11</volume>, <fpage>561</fpage>&#8211;<lpage>573</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro3049</pub-id><pub-id pub-id-type="pmcid">PMC4134018</pub-id><pub-id pub-id-type="pmid">23797173</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbeke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Lor&#233;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>Innate immune mechanisms of mRNA vaccines</article-title>. <source>Immunity</source><volume>55</volume>, <fpage>1993</fpage>&#8211;<lpage>2005</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2022.10.014</pub-id><pub-id pub-id-type="pmid">36351374</pub-id><pub-id pub-id-type="pmcid">PMC9641982</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vishwanath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hackstadt</surname><given-names>T.</given-names></name></person-group> (<year>1988</year>). <article-title>Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii</article-title>. <source>Infection Immun.</source><volume>56</volume>, <fpage>40</fpage>&#8211;<lpage>44</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.56.1.40-44.1988</pub-id><pub-id pub-id-type="pmcid">PMC259230</pub-id><pub-id pub-id-type="pmid">3335408</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vishwanath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mcdonald</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>N. G.</given-names></name></person-group> (<year>1990</year>). <article-title>A recombinant Rickettsia conorii vaccine protects Guinea pigs from experimental boutonneuse fever and Rocky Mountain spotted fever</article-title>. <source>Infection Immun.</source><volume>58</volume>, <fpage>646</fpage>&#8211;<lpage>653</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.58.3.646-653.1990</pub-id><pub-id pub-id-type="pmcid">PMC258514</pub-id><pub-id pub-id-type="pmid">2106490</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waag</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>England</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bolt</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii</article-title>. <source>Clin. Vaccine Immunol.</source><volume>15</volume>, <fpage>1505</fpage>&#8211;<lpage>1512</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00119-08</pub-id><pub-id pub-id-type="pmid">18701647</pub-id><pub-id pub-id-type="pmcid">PMC2565929</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>W. T.</given-names></name></person-group> (<year>1947</year>). <article-title>Scrub typhus vaccine; its effect on 16 cases incubating the disease</article-title>. <source>Br. Med. J.</source><volume>1</volume>, <fpage>484</fpage>&#8211;<lpage>487</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj.1.4501.484</pub-id><pub-id pub-id-type="pmid">20248030</pub-id><pub-id pub-id-type="pmcid">PMC2053023</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name></person-group> (<year>2009</year>). <article-title>The realities of biodefense vaccines against Rickettsia</article-title>. <source>Vaccine</source><volume>27</volume>, <fpage>D52</fpage>&#8211;<lpage>D55</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.045</pub-id><pub-id pub-id-type="pmid">19837287</pub-id><pub-id pub-id-type="pmcid">PMC2909128</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>OLANO</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>FENG</surname><given-names>H.-M.</given-names></name></person-group> (<year>2001</year>). <article-title>Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection</article-title>. <source>Infection Immun.</source><volume>69</volume>, <fpage>1841</fpage>&#8211;<lpage>1846</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.69.3.1841-1846.2001</pub-id><pub-id pub-id-type="pmcid">PMC98091</pub-id><pub-id pub-id-type="pmid">11179362</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei-Mei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dasch</surname><given-names>G. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Mapping of monoclonal antibody binding sites on CNBr fragments of the S-layer protein antigens of Rickettsia typhi and Rickettsia prowazekii</article-title>. <source>Mol. Immunol.</source><volume>29</volume>, <fpage>95</fpage>&#8211;<lpage>105</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0161-5890(92)90161-P</pub-id><pub-id pub-id-type="pmid">1370573</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelmsen</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Waag</surname><given-names>D. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines</article-title>. <source>Comp. Med.</source><volume>50</volume>, <fpage>374</fpage>&#8211;<lpage>378</lpage>.<pub-id pub-id-type="pmid">11020154</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willadsen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riding</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mckenna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tellam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>1989</year>). <article-title>Immunologic control of a parasitic arthropod. Identification of a protective antigen from Boophilus microplus</article-title>. <source>J. Immunol.</source><volume>143</volume>, <fpage>1346</fpage>&#8211;<lpage>1351</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.143.4.1346</pub-id><pub-id pub-id-type="pmid">2745982</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Cantrell</surname><given-names>J. L.</given-names></name></person-group> (<year>1982</year>). <article-title>Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice</article-title>. <source>Infect. Immun.</source><volume>35</volume>, <fpage>1091</fpage>&#8211;<lpage>1102</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.35.3.1091-1102.1982</pub-id><pub-id pub-id-type="pmid">7068212</pub-id><pub-id pub-id-type="pmcid">PMC351159</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Waag</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>G.</given-names></name><name name-style="western"><surname>England</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>1992</year>). <article-title>Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals</article-title>. <source>Ann. N Y Acad. Sci.</source><volume>653</volume>, <fpage>88</fpage>&#8211;<lpage>111</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1749-6632.1992.tb19633.x</pub-id><pub-id pub-id-type="pmid">1626897</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winslow</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Yager</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shilo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Volk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>F. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection</article-title>. <source>Infect. Immun.</source><volume>68</volume>, <fpage>2187</fpage>&#8211;<lpage>2195</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.68.4.2187-2195.2000</pub-id><pub-id pub-id-type="pmid">10722619</pub-id><pub-id pub-id-type="pmcid">PMC97403</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woldeyohannes</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilks</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Knibbs</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>S. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Q fever vaccine efficacy and occupational exposure risk in Queensland, Australia: A retrospective cohort study</article-title>. <source>Vaccine</source><volume>38</volume>, <fpage>6578</fpage>&#8211;<lpage>6584</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.08.006</pub-id><pub-id pub-id-type="pmid">32798141</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worswick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marmion</surname><given-names>B. P.</given-names></name></person-group> (<year>1985</year>). <article-title>Antibody responses in acute and chronic Q fever and in subjects vaccinated against Q fever</article-title>. <source>J. Med. Microbiol.</source><volume>19</volume>, <fpage>281</fpage>&#8211;<lpage>296</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1099/00222615-19-3-281</pub-id><pub-id pub-id-type="pmid">2409285</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shelite</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Goez-Rivillas</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>CD8+ T cells provide immune protection against murine disseminated endotheliotropic Orientia tsutsugamushi infection</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>11</volume>, <elocation-id>e0005763</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0005763</pub-id><pub-id pub-id-type="pmid">28723951</pub-id><pub-id pub-id-type="pmcid">PMC5536391</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yager</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bitsaktsis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mcbride</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Winslow</surname><given-names>G.</given-names></name></person-group> (<year>2005</year>). <article-title>Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice</article-title>. <source>Infection Immun.</source><volume>73</volume>, <fpage>8009</fpage>&#8211;<lpage>8016</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.73.12.8009-8016.2005</pub-id><pub-id pub-id-type="pmcid">PMC1307037</pub-id><pub-id pub-id-type="pmid">16299294</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bogdan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nazarian</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>3238</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-021-81749-9</pub-id><pub-id pub-id-type="pmid">33547334</pub-id><pub-id pub-id-type="pmcid">PMC7865008</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name></person-group> (<year>2005</year>). <article-title>Induction of protective immunity against scrub typhus with a 56-kilodalton recombinant antigen fused with a 47-kilodalton antigen of Orientia tsutsugamushi Karp</article-title>. <source>Am. J. Trop. Med. Hyg</source><volume>72</volume>, <fpage>458</fpage>&#8211;<lpage>464</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4269/ajtmh.2005.72.458</pub-id><pub-id pub-id-type="pmid">15827286</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zander</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schauder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zajac</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer</article-title>. <source>Immunity</source><volume>51</volume>, <fpage>1028</fpage>&#8211;<lpage>1042.e4</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.10.009</pub-id><pub-id pub-id-type="pmid">31810883</pub-id><pub-id pub-id-type="pmcid">PMC6929322</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>Michael J.</given-names></name></person-group> (<year>2011</year>). <article-title>CD8+ T cells: foot soldiers of the immune system</article-title>. <source>Immunity</source><volume>35</volume>, <fpage>161</fpage>&#8211;<lpage>168</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2011.07.010</pub-id><pub-id pub-id-type="pmid">21867926</pub-id><pub-id pub-id-type="pmcid">PMC3303224</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.-Z.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.-J.</given-names></name></person-group> (<year>2006</year>). <article-title>A mutation inactivating the methyltransferase gene in avirulent Madrid E strain of Rickettsia prowazekii reverted to wild type in the virulent revertant strain Evir</article-title>. <source>Vaccine</source><volume>24</volume>, <fpage>2317</fpage>&#8211;<lpage>2323</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.11.044</pub-id><pub-id pub-id-type="pmid">16364512</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Mechanisms of Vaccine-Induced Protective Immunity against Coxiella burnetii Infection in BALB/c Mice</article-title>. <source>J. Immunol.</source><volume>179</volume>, <fpage>8372</fpage>&#8211;<lpage>8380</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.179.12.8372</pub-id><pub-id pub-id-type="pmid">18056383</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Antenucci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Villumsen</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Bojesen</surname><given-names>A. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Bacterial outer membrane vesicles as a versatile tool in vaccine research and the fight against antimicrobial resistance</article-title>. <source>mBio</source><volume>12</volume>, <fpage>e01707</fpage>&#8211;<lpage>e01721</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/mBio.01707-21</pub-id><pub-id pub-id-type="pmid">34372691</pub-id><pub-id pub-id-type="pmcid">PMC8406158</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>